[{"text": "Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss editorial-team@simplywallst.com (Simply Wall St) Sat, Jan 25, 2025, 3:35 PM 3 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders should be happy to see the share price up 16% in the last month. But that doesn't change the fact that the returns over the last year have been disappointing. Specifically, the stock price slipped by 68% in that time. Some might say the recent bounce is to be expected after such a bad drop. You could argue that the sell-off was too severe. On a more encouraging note the company has added US$74m to its market cap in just the last 7 days, so let's see if we can determine what's driven the one-year loss for shareholders. View our latest analysis for EyePoint Pharmaceuticals EyePoint Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last year EyePoint Pharmaceuticals saw its revenue grow by 7.5%. That's not a very high growth rate considering it doesn't make profits. Without profits, and with revenue growth sluggish, you get a 68% loss for shareholders, over the year. Like many holders, we really want to see better revenue growth in companies that lose money. Of course, the market can be too impatient at times. Why not take a closer look at this one so you're ready to pounce if growth does accelerate. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). NasdaqGM:EYPT Earnings and Revenue Growth January 25th 2025 We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling EyePoint Pharmaceuticals stock, you should check out this free report showing analyst profit forecasts . A Different Perspective EyePoint Pharmaceuticals shareholders are down 68% for the year, but the market itself is up 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9% over the last half decade. We realise that Baron Rothschild has said investors should \"buy when there is blood on the streets\", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand EyePoint Pharmaceuticals better, we need to consider many other factors. Take risks, for example - EyePoint Pharmaceuticals has 3 warning signs (and 1 which can't be ignored) we think you should know about. Story Continues If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2025-01-25T12:35:54+00:00", "sentiment": {"score": -0.8588003627955914, "confidence": 0.904180109500885, "probabilities": {"positive": 0.045379746705293655, "negative": 0.904180109500885, "neutral": 0.05044020712375641}}, "embedding": [-0.032472386956214905, -0.11920894682407379, 0.055556558072566986, -0.0227853711694479, 0.010190208442509174, 0.012222019955515862, 0.037735749036073685, 0.19132405519485474, 0.08581390976905823, 0.08336305618286133, -0.09225326776504517, 0.18290093541145325, -0.028750700876116753, 0.0009068567305803299, -0.11460354924201965, -0.058178044855594635, -0.07386618852615356, -0.03164481744170189, -0.02709304913878441, 0.0378464013338089, -0.07692398130893707, -0.09692329168319702, 0.05297384411096573, 0.004976455122232437, 0.0038482851814478636, 0.0577494353055954, -0.07790607213973999, 0.001536879688501358, -0.16707603633403778, -0.1060212105512619, -0.0661163479089737, 0.08010894060134888, 0.12107036262750626, 0.008190114051103592, -0.06834670156240463, 0.03239725902676582, 0.0019786739721894264, 0.10352690517902374, 0.06229798495769501, 0.0011226639617234468, -0.02392548695206642, -0.061169229447841644, -0.10335297882556915, -0.00811680406332016, 0.020891372114419937, -0.22897577285766602, 0.023506727069616318, -0.003755565732717514, 0.0077832285314798355, 0.05430590361356735, -0.19997070729732513, -0.051890403032302856, -0.0023094099014997482, -0.015558607876300812, 0.015882937237620354, 0.07069605588912964, -0.16090542078018188, -0.06462804973125458, 0.030674472451210022, -0.026922686025500298, 0.06865659356117249, 0.03982088342308998, 0.07587230205535889, -0.041475117206573486, 0.1496690809726715, -0.008801974356174469, 0.13729029893875122, 0.029780831187963486, -0.06708019971847534, 0.07030898332595825, 0.023230763152241707, -0.012690695002675056, -0.0139690600335598, -0.003459413070231676, -0.13132935762405396, 0.10950849205255508, 0.08322077989578247, 0.026887444779276848, 0.08056503534317017, -0.020726805552840233, 0.16899122297763824, 0.05870401859283447, -0.14966127276420593, -0.09807834029197693, -0.0650712251663208, 0.0014434782788157463, 0.12736259400844574, -0.0014289449900388718, 0.09890353679656982, -0.02656509354710579, 0.1364806592464447, 0.030797075480222702, -0.07814472168684006, -0.0818859338760376, 0.12107576429843903, -0.0006952998228371143, -0.15678218007087708, -0.09125888347625732, -0.03807510435581207, 0.055532585829496384, 0.12172645330429077, 0.17608344554901123, -0.07240422070026398, -0.12839345633983612, -0.03363904356956482, -0.14449506998062134, 0.048998650163412094, 0.044473208487033844, -0.044228699058294296, 0.06924314796924591, -0.07620830088853836, 0.11264011263847351, -0.1104683130979538, -0.053504057228565216, -0.023526795208454132, 0.04961351305246353, -0.0661792904138565, -0.06868349760770798, 0.04340900853276253, 0.08305859565734863, 0.056533023715019226, 0.16151320934295654, 0.06431606411933899, 0.005631377454847097, 0.03722609579563141, 0.02243722602725029, -0.09888458251953125, 1.1931227987911878e-32, -0.012758282944560051, 0.017158379778265953, 0.03866752237081528, -0.12176713347434998, -0.1091461032629013, 0.028829757124185562, 0.04430878534913063, 0.00020088814198970795, -0.05872543156147003, -0.1067676693201065, -0.2006528079509735, 0.02421421930193901, 0.010512033477425575, -0.03784734010696411, 0.07092636823654175, -0.09103263169527054, -0.0038839206099510193, 0.08297890424728394, 0.04323625564575195, -0.09376300126314163, -0.08089737594127655, -0.033981189131736755, -0.0937468484044075, 0.00959212426096201, 0.045233581215143204, 0.020703835412859917, -0.0899680107831955, 0.11164532601833344, -0.030445782467722893, 0.01688620075583458, 0.005960185080766678, 0.04251775145530701, -0.049771979451179504, -0.08821888267993927, -0.005083201453089714, -0.12330978363752365, -0.09467464685440063, 0.015279168263077736, 0.1940321922302246, -0.031904999166727066, -0.11319679766893387, 0.0841805636882782, -0.06085562705993652, -0.07665975391864777, -0.0474533773958683, 0.08427278697490692, -0.03015841916203499, 0.03521203622221947, -0.028667442500591278, -0.07726205140352249, 0.06501670926809311, 0.005155901424586773, -0.06755523383617401, -0.09520163387060165, 0.030253086239099503, 0.1282009482383728, -0.02512027695775032, -0.15381339192390442, 0.07042965292930603, 0.1180710569024086, 0.020493600517511368, 0.12506261467933655, 0.0242844857275486, -0.0034773419611155987, -0.24013671278953552, 0.1649775505065918, -0.011774890124797821, 0.0745106115937233, -0.05590302497148514, 0.15386155247688293, 0.04556781426072121, -0.0771360918879509, 0.10776899009943008, -0.08506748825311661, 0.13185623288154602, -0.017324009910225868, -0.01984497718513012, 0.010172627866268158, 0.07324904203414917, 0.07314954698085785, 0.08347583562135696, -0.06967848539352417, 0.06279873102903366, -0.019137956202030182, -0.004257437773048878, -0.063278928399086, 0.11856681108474731, 0.00796458963304758, -0.04479900375008583, -0.013354393653571606, -0.0006533628329634666, -0.060618478804826736, -0.11154121160507202, 0.13513094186782837, 0.013709824532270432, -1.098094880381554e-32, 0.03505054861307144, 0.0284761693328619, -9.244773536920547e-05, -0.06076713651418686, -0.10717322677373886, -0.004172610584646463, 0.09602276235818863, 0.06063946709036827, -0.06683800369501114, -0.05266709253191948, 0.02870936691761017, 0.032604265958070755, -0.089442178606987, 0.07932280004024506, -0.09203656762838364, -0.0034104499500244856, 0.1568695604801178, -0.16852188110351562, -0.006832175888121128, -0.062197864055633545, 0.01568267121911049, 0.1487809419631958, -0.18460384011268616, 0.03400498628616333, 0.011677166447043419, 0.0883706659078598, 0.0383429192006588, 0.11748304963111877, -0.019466115161776543, -0.08578719943761826, -0.09991739690303802, -0.013994346372783184, -0.11948725581169128, 0.07149949669837952, 0.033993300050497055, 0.05251101404428482, -0.03948152810335159, -0.23575547337532043, -0.06438660621643066, -0.07634453475475311, 0.14036116003990173, 0.06509053707122803, 0.05612548813223839, -0.026446279138326645, 0.11541134864091873, 0.07950068265199661, 0.1438218057155609, 0.0922783762216568, 0.14267094433307648, 0.10688003897666931, 0.013814639300107956, 0.034471545368433, -0.030428744852542877, 0.057107988744974136, -0.08796701580286026, 0.135366290807724, -0.029619012027978897, -0.06756915152072906, -0.09477987885475159, 0.02387864701449871, 0.016744408756494522, 0.02814430370926857, -0.04951179027557373, 0.027315808460116386, -0.018818458542227745, -0.04145362973213196, 0.060196444392204285, -0.1064390242099762, 0.07704080641269684, -0.1552838683128357, 0.021753758192062378, -0.1114974319934845, 0.05055835843086243, -0.08013509213924408, -0.05626475811004639, 0.23260819911956787, -0.045547422021627426, -0.050660088658332825, -0.054908763617277145, -0.01941240206360817, 0.034765057265758514, 0.029820656403899193, 0.003227406181395054, 0.08279197663068771, -0.13106510043144226, 0.09768177568912506, 0.005058038979768753, -0.08800747990608215, -0.03067585453391075, 0.03776092082262039, -0.06912533938884735, -0.21273624897003174, -0.15743856132030487, 0.04606594145298004, 0.11279353499412537, -9.98828824094744e-08, -0.0013249944895505905, -0.05726304650306702, 0.10306839644908905, 0.0006035827100276947, 0.1623402088880539, -0.11349426954984665, 0.08969346433877945, 0.044139813631772995, 0.14710985124111176, 0.07604875415563583, 0.07788314670324326, 0.02722807228565216, -0.1894862949848175, 0.16539016366004944, -0.05079273134469986, 0.028509346768260002, -0.13223877549171448, 0.013575015589594841, -0.04909396916627884, -0.13002832233905792, -0.06269428133964539, 0.05425790697336197, 0.0993591845035553, 0.00670948252081871, 0.05401266738772392, -0.010877552442252636, -0.04297880455851555, 0.044962119311094284, -0.04480374604463577, -0.032591499388217926, 0.12624236941337585, -0.03066825121641159, 0.11577007174491882, 0.018840152770280838, -0.0022772513329982758, -0.031765278428792953, 0.06813453882932663, 0.06667670607566833, 0.05357851833105087, 0.12683826684951782, -0.052770890295505524, 0.030583679676055908, 0.06684724241495132, 0.0028576161712408066, -0.0763958990573883, -0.09225644916296005, -0.07820862531661987, 0.103303924202919, 0.051552124321460724, -0.21216411888599396, 0.1229112446308136, -0.046464502811431885, -0.015511740930378437, -0.01741374470293522, 0.1259724348783493, -0.026156673207879066, -0.13945424556732178, -0.045614004135131836, -0.1606287956237793, 0.014830078929662704, -0.006685826927423477, -0.1673162579536438, 0.024857155978679657, 0.17053768038749695], "changes": {"1wk": -4.613470589494362}}, {"text": "EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EyePoint Pharmaceuticals, Inc. Thu, Jan 16, 2025, 3:00 PM 2 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.69 per share, the closing price of EyePoint Pharmaceuticals\u2019 common stock on January 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee\u2019s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee\u2019s continued service with EyePoint Pharmaceuticals through the applicable vesting dates. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E\u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU\u2122 (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E\u2122. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E\u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert\u00ae drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Story Continues Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. For EyePoint Pharmaceuticals: Investors: Christina Tartaglia Precision AQ Direct: 212-698-8700 christina.tartaglia@precisionaq.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2025-01-16T12:00:00+00:00", "sentiment": {"score": 0.07999858818948269, "confidence": 0.08974925428628922, "probabilities": {"positive": 0.08974925428628922, "negative": 0.009750666096806526, "neutral": 0.9005001187324524}}, "embedding": [-0.10330177843570709, -0.030257627367973328, 0.0633092001080513, -0.1518833190202713, -0.06410887092351913, -0.0016917698085308075, 0.08610665798187256, 0.2717454433441162, 0.09929128736257553, 0.07075215876102448, 0.013357127085328102, 0.07746691256761551, -0.004477262496948242, 0.0885319858789444, -0.05392299219965935, 0.044378023594617844, -0.08682999014854431, -0.00479840487241745, -0.058838315308094025, 0.027165716513991356, 0.12445089221000671, -0.08581769466400146, -0.0242901798337698, -0.03917337954044342, -0.03333593159914017, 0.012506090104579926, -0.018867576494812965, 0.02270333096385002, -0.14590270817279816, -0.09695438295602798, 0.02876712754368782, 0.0590793639421463, 0.025583729147911072, -0.1385076344013214, -0.06660671532154083, 0.029483690857887268, -0.23026755452156067, -0.02218589372932911, -0.1362789273262024, 0.004580712877213955, -0.11743880063295364, -0.0945063903927803, -0.1776077151298523, 0.10938306897878647, 0.09053323417901993, -0.19778475165367126, -0.05563925951719284, 0.11216524988412857, -0.015398962423205376, 0.09243661165237427, -0.12808284163475037, -0.04111780598759651, -0.052454255521297455, 0.08510211110115051, -0.03635735437273979, 0.010985471308231354, -0.24479439854621887, 0.007953392341732979, 0.07338689267635345, 0.02013474516570568, 0.016991285607218742, -0.017539195716381073, 0.0236566923558712, 0.029828310012817383, 0.06146793067455292, 0.0654090940952301, 0.11558510363101959, -0.07007090747356415, 0.038148168474435806, -0.04242468997836113, 0.024576405063271523, -0.05951070412993431, 0.035039205104112625, 0.07357900589704514, -0.11558309197425842, 0.2309190332889557, 0.09463748335838318, 0.05952886492013931, 0.05744840204715729, -0.14244136214256287, 0.10258929431438446, 0.08615653216838837, 0.0358932763338089, -0.02149752527475357, 0.031061990186572075, -0.02185225859284401, -0.004761510994285345, 0.10673941671848297, 0.18135374784469604, -0.016490180045366287, 0.1158200353384018, -0.033496033400297165, -0.10299354791641235, -0.11820222437381744, -0.04079204797744751, -0.1006271243095398, -0.18565869331359863, -0.04026617482304573, -0.09015367925167084, -0.002278159372508526, 0.06349949538707733, -0.01904873363673687, -0.06723923981189728, -0.08017022162675858, -0.03200211003422737, -0.07528288662433624, 0.1002260148525238, -0.05079197138547897, 0.08464908599853516, 0.04275713115930557, -0.17253589630126953, 0.032704778015613556, -0.03920977562665939, 0.01389199960976839, -0.16221648454666138, 0.21160238981246948, -0.09239165484905243, -0.05169912427663803, 0.3052724003791809, -0.08201731741428375, 0.15480419993400574, 0.07937251776456833, 0.05540159344673157, -0.14650626480579376, -0.004736587405204773, -0.0641084834933281, -0.1414295732975006, 8.305124727948704e-33, -0.035670455545186996, 0.06445005536079407, -0.01030825823545456, -0.04152781516313553, 0.028238927945494652, -0.04539571702480316, 0.09876292943954468, 0.08644597232341766, -0.28820133209228516, -0.02700747922062874, -0.23192903399467468, -0.020703380927443504, -0.0014620479196310043, 0.17763063311576843, -0.0019252323545515537, -0.09405524283647537, 0.043603990226984024, 0.20749527215957642, 0.0486314557492733, -0.0008977875113487244, -0.021221261471509933, 0.07178705185651779, -0.09201322495937347, 0.08536310493946075, -0.002783913165330887, 0.05219068005681038, -0.05555025115609169, 0.07275819778442383, 0.06592129915952682, 0.03312676399946213, -0.04938776046037674, 0.09408556669950485, 0.050075963139534, -0.1420973241329193, 0.04525382071733475, -0.08059559762477875, -0.0031624119728803635, -0.12374762445688248, 0.19337263703346252, -0.007476599887013435, 0.02530576102435589, 0.08958713710308075, -0.041079312562942505, -0.11326783895492554, 0.0474269837141037, 0.08645526319742203, -0.0931692123413086, 0.16423776745796204, -0.037563372403383255, 0.0345306396484375, -0.026108354330062866, 0.0022117290645837784, -0.09800808131694794, -0.11502343416213989, -0.10691326856613159, 0.029601091518998146, -0.20372599363327026, -0.055404819548130035, 0.1418357789516449, 0.11626435816287994, -0.024288464337587357, 0.15700650215148926, -0.03640379011631012, 0.0624496191740036, -0.1829669177532196, 0.009860859252512455, -0.017669470980763435, -0.08708622306585312, -0.028293240815401077, 0.06624077260494232, -0.01252721156924963, -0.007969474419951439, 0.19681167602539062, -0.06534551829099655, 0.07125788927078247, -0.0878605768084526, 0.055058468133211136, 0.13128554821014404, 0.10760588943958282, 0.018875036388635635, -0.02576087787747383, -0.015026448294520378, -0.03483780100941658, 0.037817176431417465, 0.05649612471461296, -0.0330604687333107, -0.00040159793570637703, 0.03689618408679962, -0.1269320696592331, -0.08494791388511658, 0.16482560336589813, -0.04535292834043503, -0.07828220725059509, 0.08555150777101517, 0.06783545017242432, -7.870213123979566e-33, -0.02875327132642269, -0.021600883454084396, 0.03456365689635277, -0.019124701619148254, 0.019035425037145615, 0.15164625644683838, 0.06358351558446884, -0.06561607122421265, 0.12830103933811188, -0.04384136199951172, 0.023037543520331383, 0.037445228546857834, 0.016911005601286888, -0.09483741223812103, -0.09984239935874939, 0.05645628273487091, -0.06034854054450989, -0.10423529148101807, -0.12103277444839478, 0.053089119493961334, 0.04323286563158035, 0.09853938221931458, -0.08623994141817093, 0.07480103522539139, 0.1351861208677292, 0.1165233850479126, 0.1406518518924713, 0.03013772889971733, 0.01606655865907669, 0.02720770612359047, -0.12364490330219269, -0.021276777610182762, -0.36428484320640564, 0.09776544570922852, 0.04537936672568321, -0.02485560066998005, 0.08975084871053696, -0.21077105402946472, 0.014932986348867416, -0.011432314291596413, 0.1269572526216507, -0.10620002448558807, 0.09064541757106781, 0.025728801265358925, 0.03536028042435646, -0.013774549588561058, 0.0870436355471611, -0.0560506209731102, 0.17778077721595764, -0.0491974912583828, -0.09678943455219269, 0.02997533790767193, 0.06347212940454483, 0.08112561702728271, -0.09355387091636658, 0.03327789157629013, 0.04981694370508194, -0.0290018692612648, 0.040594615042209625, -0.025396447628736496, 0.1012963354587555, 0.004159172065556049, 0.02693316712975502, -0.04164254665374756, 0.09061985462903976, -0.013828665018081665, 0.09391538798809052, 0.007207730785012245, 0.05032242089509964, -0.1282065510749817, 0.013589650392532349, -0.136552631855011, 0.1128484457731247, -0.13576576113700867, 0.03431478887796402, 0.10977546870708466, 0.06345774978399277, -0.1571042239665985, -0.19191265106201172, 0.011386233381927013, 0.08464889973402023, -0.07666947692632675, -0.012030559591948986, 0.15037038922309875, -0.010868757963180542, 0.05526817962527275, 0.10250502079725266, 0.021993327885866165, -0.019182946532964706, 0.06421934813261032, -0.12844793498516083, -0.09414675086736679, -0.10685141384601593, 0.20741334557533264, 0.054087601602077484, -1.0020291085766075e-07, 0.058222681283950806, -0.06058255955576897, -0.011601220816373825, -0.060771241784095764, 0.08213620632886887, -0.13629081845283508, -0.016100572422146797, 0.11140768229961395, -0.006267196498811245, 0.05035783350467682, 0.0414535291492939, 0.1488620936870575, -0.12034134566783905, 0.10807950794696808, -0.04705198109149933, 0.00043150410056114197, -0.019654909148812294, 0.0671149343252182, -0.08559069037437439, -0.08238665759563446, -0.17498734593391418, -0.017777644097805023, 0.01024569757282734, -0.07978543639183044, -0.03085961565375328, -0.028582200407981873, 0.02864602580666542, 0.11171295493841171, 0.02712908387184143, 0.022700799629092216, 0.12241794168949127, 0.02642219513654709, 0.1078319251537323, 0.054789382964372635, -0.050419602543115616, -0.12837938964366913, 0.030705628916621208, 0.18288873136043549, 0.02785629779100418, 0.11829175055027008, -0.08709585666656494, 0.013232402503490448, 0.06506391614675522, 0.06456195563077927, -0.0016822321340441704, -0.03348444774746895, -0.17065846920013428, -0.01090990286320448, -0.06069213151931763, -0.11236300319433212, 0.010746486485004425, 0.044810786843299866, -0.0842391774058342, -0.06533578783273697, -0.01051083579659462, 0.017071165144443512, -0.03668852150440216, -0.10424879938364029, -0.03897630423307419, -0.08007954806089401, 0.0128416046500206, -0.15564119815826416, 0.08056387305259705, 0.11492838710546494], "changes": {"1wk": 19.94498335497247}}, {"text": "EyePoint Provides Company Update and Anticipated Development Milestones for 2025 EyePoint Pharmaceuticals, Inc. Mon, Jan 13, 2025, 3:00 PM 10 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. \u2013\u00a0Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule \u2013 \u2013\u00a0Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 \u2013 \u2013\u00a0Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors \u2013 \u2013\u00a0Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 \u2013 \u2013\u00a0Presenting at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT \u2013 WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today provided a company update and anticipated 2025 milestones for its lead product candidate, DURAVYU\u2122\u00a0(vorolanib intravitreal insert), f/k/a EYP-1901. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor (TKI) formulated in proprietary bioerodible Durasert E\u2122 for sustained intraocular delivery. \u201c2024 was an exceptional year for EyePoint, positioning us for continued success and execution in 2025,\u201d said Jay Duker, M.D., President and Chief Executive Officer. \u201cMost importantly, as we step into 2025, both of our global Phase 3 clinical trials for DURAVYU in wet AMD are now fully underway with enrollment in both trials exceeding our expectations. The LUGANO trial has already enrolled approximately one-third of planned patients, and the LUCIA trial is tracking ahead of schedule after an accelerated initiation in December. We expect to fully enroll these trials in the second half of 2025. We remain very excited by the large market opportunity for DURAVYU in diabetic macular edema (DME) where 16-week interim data demonstrated early and sustained improvement in BCVA and CST. We look forward to final VERONA data as well as alignment with the FDA and EMA in the coming months to finalize our Phase 3 plan for this important indication.\u201d Dr. Duker continued, \u201cWe continue our track record of strong execution with the opening of our new, state-of-the-art Northbridge, MA manufacturing facility in the fall of 2024. The 40,000 plus square-foot manufacturing facility reflects our commitment to quality and commercial readiness for DURAVYU. With two simultaneous Phase 3 clinical trials underway, the most robust clinical dataset of all long-acting treatments in development for wet AMD, an impressive patent portfolio for DURAVYU, and a strong balance sheet, we are well-positioned to advance our mission of bringing potentially life-changing therapeutics to patients suffering from serious retinal diseases globally.\u201d Story Continues The Leader in Sustained Ocular Drug Delivery : Global Phase 3 LUGANO and LUCIA pivotal trials of DURAVYU in wet AMD underway. Enrollment completion of both trials is expected in 2H 2025, with topline data anticipated in 2026. DURAVYU Phase 3 pivotal design is the only sustained delivery wet AMD program evaluating six-month re-dosing in both trials. The LUGANO and LUCIA trials are also designed to provide data on the efficacy, durability, and safety of DURAVYU and provide the retina community with valuable insight on how DURAVYU could be used in \u2018real-world\u2019 practice. DURAVYU was evaluated in the largest Phase 2 clinical trial to date (DAVIO 2) of all sustained delivery programs in development, meeting all primary and secondary endpoints. DURAVYU is the only sustained release TKI being evaluated in DME. Positive interim 16-week data from the Phase 2 VERONA clinical trial demonstrated DURAVYU 2.7mg meaningfully improved patients with active DME better than aflibercept alone both anatomically and visually with CST (central subfield thickness) improvement of 68.1 microns and a BCVA gain of +8.9 letters vs. baseline. Notably, both DURAVYU doses showed an immediate benefit demonstrating the unique drug release profile of DURAVYU. Full topline data from the Phase 2 VERONA clinical trial is expected in 1Q 2025 with interactions with the FDA and the European Medicines Agency (EMA) on Phase 3 plans to follow. DURAVYU has the most robust safety database among sustained delivery treatments with over 190 patients dosed across multiple indications, with no DURAVYU related ocular or systemic serious adverse events reported. EyePoint\u2019s Durasert technology has been utilized in four FDA approved products with an established favorable safety profile in thousands of patients. Corporate Updates In January 2025, EyePoint appointed renowned retina specialist and industry pioneer Reginald J. Sanders, M.D., FASRS to the Board of Directors. In October 2024, EyePoint announced the opening of its Northbridge, MA cGMP commercial manufacturing facility built to meet U.S. FDA and EMA standards. It will support global manufacturing across the Company\u2019s portfolio, including lead pipeline asset, DURAVYU\u2122\u00a0upon potential regulatory approval. The facility is strategically designed to support the Company\u2019s next phase of growth and broadens EyePoint\u2019s manufacturing capabilities with capacity for pipeline expansion. Approximately $370 million 1 of cash and investments at December 31, 2024 with cash runway into 2027 beyond topline Phase 3 data for DURAVYU in wet AMD expected in 2026. EyePoint will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. Jay S. Duker, M.D., President and Chief Executive Officer, will provide a company update on clinical and regulatory progress and highlight upcoming milestones. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com . 1 Unaudited estimate as of December 31, 2024. About DURAVYU\u2122 DURAVYU\u2122, f/k/a EYP-1901, is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. DURAVYU delivers vorolanib, a potent, selective and patent-protected tyrosine kinase inhibitor (TKI) as a solid bioerodible insert using EyePoint\u2019s proprietary sustained-release Durasert E\u2122\u00a0technology. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor inhibitor, inhibiting all VEGF receptors. In an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection and may have antifibrotic benefits as it also blocks PDGF. DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection in the physician's office. DURAVYU is immediately bioavailable with zero-order kinetics release for at least six months. Positive data from Phase 1 and Phase 2 (DAVIO 2) clinical trials of DURAVYU in wet AMD demonstrated clinically meaningful efficacy data with stable visual acuity and CST and a favorable safety profile. Data from DAVIO 2 demonstrated an impressive treatment burden reduction of approximately 88% six months after treatment with DURAVYU, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection. The DAVIO 2 clinical trial data supported the initiation of the current global Phase 3 clinical trials, LUGANO and LUCIA in wet AMD. DURAVYU is also currently being studied in the Phase 2 VERONA trial for diabetic macular edema (DME) with positive interim 16-week results for both safety and efficacy. Full topline data is expected in the first quarter of 2025. About EyePoint Pharmaceuticals EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E\u2122\u00a0technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU\u2122 is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E\u2122. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in\u00a0the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). Full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E\u2122\u00a0to potentially improve outcomes in serious retinal diseases. The proven Durasert \u00ae drug delivery technology has been safely administered to thousands of patient eyes across four\u00a0U.S.\u00a0FDA approved products.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the announcement of full topline data from the VERONA trial in the first quarter of 2025 and the progress of our ongoing LUGANO and LUCIA trials; the belief that the interim results from the VERONA trial support DURAVYU\u2019s potential to advance to non-inferiority pivotal trials; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as \u201cwill,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cintends,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cmay,\u201d other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint\u2019s actual results to be materially different than those expressed in or implied by EyePoint\u2019s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company\u2019s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company\u2019s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company\u2019s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company\u2019s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney\u2019s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company\u2019s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Precision AQ Direct: 212-698-8700 christina.tartaglia@precisionaq.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2025-01-13T12:00:00+00:00", "sentiment": {"score": 0.8460133681073785, "confidence": 0.8551486730575562, "probabilities": {"positive": 0.8551486730575562, "negative": 0.00913530495017767, "neutral": 0.13571611046791077}}, "embedding": [-0.12621444463729858, -0.12272801995277405, 0.0693451464176178, -0.09426270425319672, 0.0010987214045599103, -0.19282689690589905, -0.10480698198080063, 0.18668854236602783, 0.08399602770805359, 0.12716305255889893, -0.08053426444530487, 0.08831215649843216, -0.017544882372021675, 0.11589601635932922, -0.04005870968103409, 0.04969879239797592, -0.01562678813934326, -0.04217621684074402, -0.02360599860548973, 0.08812962472438812, 0.15331529080867767, -0.04417753964662552, 0.02687254175543785, 0.04682756960391998, -0.13150453567504883, 0.029213756322860718, 0.01313142292201519, -0.04384855180978775, -0.14877361059188843, -0.09554008394479752, 0.036566779017448425, 0.06969988346099854, -0.06470590829849243, -0.07505021244287491, -0.015147250145673752, -0.02248351089656353, -0.13459959626197815, -0.06417442858219147, -0.19203877449035645, -0.09830057621002197, -0.10652410984039307, -0.0821351706981659, -0.18109029531478882, 0.12438943237066269, 0.21629050374031067, -0.21520119905471802, -0.06695784628391266, 0.10965535789728165, -0.06696437299251556, 0.16818556189537048, -0.1621577888727188, -0.11731217801570892, 0.007822361774742603, 0.08571034669876099, -0.050645194947719574, 0.05993248522281647, -0.20974230766296387, 0.023994235321879387, 0.10878433287143707, -0.00101496372371912, 0.019791003316640854, -0.06708893179893494, 0.037858765572309494, 0.0040984852239489555, -0.06104487180709839, 0.03712750971317291, 0.07314127683639526, -0.03946954011917114, 0.027747787535190582, -0.03916916996240616, 0.04358724132180214, -0.05648966133594513, 0.07696810364723206, 0.05710618197917938, -0.018573101609945297, 0.10160057991743088, 0.13784626126289368, 0.06418640911579132, 0.1300591379404068, -0.12877985835075378, 0.11266699433326721, 0.029099661856889725, 0.06719452887773514, 0.036525268107652664, 0.07526418566703796, -0.009371576830744743, -0.029032781720161438, 0.09033088386058807, 0.07501097023487091, -0.07761721312999725, 0.13792139291763306, 0.014143340289592743, -0.08854078501462936, 0.0263533778488636, -0.027307379990816116, 0.008787820115685463, -0.11572352051734924, 0.007893652655184269, -0.015597973018884659, 0.011783772148191929, -0.0016225893050432205, 0.016129910945892334, -0.040358446538448334, -0.09556354582309723, -0.04526519775390625, -0.08679869771003723, 0.1540485918521881, -0.04405975341796875, 0.03955067694187164, 0.00030360370874404907, -0.0542764887213707, 0.05691428855061531, 0.07169437408447266, 0.060339365154504776, -0.06910476088523865, 0.14868411421775818, -0.10231848061084747, 0.029184717684984207, 0.34642258286476135, -0.03608844429254532, 0.07106919586658478, 0.07615964859724045, 0.04321838915348053, -0.11385701596736908, 0.1464943289756775, 0.07171621918678284, -0.017632730305194855, 1.1188089275529659e-32, 0.009766796603798866, 0.002540445886552334, -0.04712143912911415, 0.09399648755788803, -0.07203454524278641, -0.11464455723762512, 0.0746479332447052, 0.061599403619766235, -0.25509902834892273, -0.09916956722736359, -0.25741153955459595, -0.07061778008937836, -0.05133068561553955, 0.20920222997665405, -0.0488143265247345, -0.14828906953334808, 0.06369072198867798, 0.15132758021354675, -0.03798847645521164, 0.022392336279153824, -0.017477670684456825, 0.07379498332738876, -0.03213861584663391, 0.02256792038679123, -0.040807630866765976, 0.15648505091667175, -0.02466731145977974, 0.07176326215267181, 0.1501123011112213, 0.09260284155607224, -0.14420200884342194, 0.06166379153728485, 0.09638824313879013, -0.10704256594181061, -0.004138124641031027, 0.026745088398456573, -0.05144575983285904, -0.14929792284965515, 0.044988855719566345, 0.04623416066169739, 0.0008547892794013023, 0.1283021867275238, -0.10784155875444412, -0.10791865736246109, 0.04021379351615906, -0.012685215100646019, -0.08173419535160065, 0.13109304010868073, 0.004533158149570227, -0.07791535556316376, -0.06563700735569, -0.052458155900239944, -0.03815873712301254, -0.13062109053134918, -0.019052453339099884, 0.037052638828754425, -0.1928723156452179, -0.12408611178398132, 0.15595242381095886, 0.07014718651771545, -0.006972904317080975, 0.09781555086374283, -0.08174849301576614, 0.13543161749839783, -0.10849917680025101, -0.02180512621998787, 0.06669553369283676, 0.03390900790691376, -0.07874413579702377, -0.08520908653736115, 0.025825921446084976, -0.04115857928991318, 0.08698761463165283, -0.003945614211261272, 0.12004409730434418, -0.007271460723131895, 0.15439169108867645, 0.09920907765626907, 0.09947723895311356, 0.012525243684649467, -0.013891059905290604, 0.006150810047984123, -0.09032180905342102, 0.06778621673583984, 0.06162112206220627, -0.030316581949591637, 0.03042495623230934, -0.0065385568886995316, -0.13417592644691467, -0.06865301728248596, 0.19395670294761658, -0.008201551623642445, -0.019474849104881287, 0.04803737252950668, 0.043769922107458115, -1.0141070579780493e-32, -0.02429361082613468, -0.011222900822758675, 0.04279925674200058, -0.010240147821605206, -0.012799786403775215, 0.1428246945142746, 0.05274351313710213, -0.13247956335544586, 0.21758991479873657, -0.21830040216445923, -0.023560892790555954, -0.015038009732961655, -0.0004760539159178734, -0.059834886342287064, -0.1251830756664276, 0.12014144659042358, -0.056479163467884064, -0.11797882616519928, -0.16457566618919373, 0.022059472277760506, 0.07023629546165466, 0.04023590311408043, -0.05104665458202362, -0.004623389802873135, 0.06326423585414886, 0.07803139835596085, 0.18224318325519562, 0.033543020486831665, -0.03737315163016319, 0.013871807605028152, -0.12267018109560013, -0.006422614678740501, -0.259628564119339, 0.056750498712062836, -0.00954846665263176, 0.10371170938014984, 0.027548205107450485, -0.21389301121234894, -0.06029850244522095, -0.0913732573390007, 0.05833035707473755, -0.028809959068894386, -0.036273639649152756, -0.03693803399801254, 0.04750552773475647, 0.05467415601015091, 0.04874470829963684, 0.04416811466217041, 0.12296853214502335, -0.03752829506993294, -0.10771037638187408, 0.035815343260765076, 0.013446008786559105, -0.025706885382533073, -0.057781368494033813, -0.03780139237642288, 0.03926220163702965, -0.00806429609656334, -0.06069374829530716, 0.07724207639694214, 0.025574808940291405, -0.04434609413146973, 0.056142039597034454, -0.01636267639696598, 0.08683353662490845, 0.19743269681930542, 0.1313927173614502, 0.058101508766412735, 0.10476171970367432, -0.10897516459226608, 0.033308327198028564, -0.0779329240322113, -0.1608942151069641, -0.11198806762695312, 0.03496968001127243, 0.07848291844129562, -0.0009836092358455062, -0.1228051707148552, -0.1917353868484497, -0.037545111030340195, 0.06894014775753021, -0.08536013960838318, -0.05862424522638321, 0.1230144053697586, 0.017897196114063263, 0.10148429870605469, 0.10713803768157959, -0.08106047660112381, -0.018919508904218674, 0.07743937522172928, -0.13770735263824463, -0.05592598021030426, -0.19116079807281494, 0.21096011996269226, 0.10745129734277725, -1.0053717858227174e-07, 0.0768706426024437, 0.012696131132543087, 0.04430394992232323, -0.07574757933616638, 0.05019050091505051, -0.1156688779592514, -0.052657246589660645, 0.10656853020191193, -0.020168475806713104, 0.07783590257167816, 0.012101547792553902, 0.17691275477409363, -0.020422838628292084, -0.02830529771745205, 0.029796693474054337, 0.10291201621294022, 0.048343345522880554, 0.07014741003513336, -0.08138340711593628, -0.06206052750349045, -0.05837763473391533, -0.0010973166208714247, 0.0951092466711998, -0.12632685899734497, 0.043292444199323654, -0.07759866863489151, -0.05750352889299393, 0.10058030486106873, 0.02599451132118702, -0.10404020547866821, 0.10654488205909729, 0.014919999055564404, 0.08803631365299225, 0.0012451810762286186, -0.03806706517934799, -0.1287878155708313, -0.006678672507405281, 0.17681288719177246, 0.08591748028993607, 0.13034212589263916, -0.07876458764076233, 0.0644911378622055, 0.05870424956083298, 0.027474958449602127, -0.06801692396402359, -0.12842290103435516, -0.048548486083745956, 0.0034848302602767944, -0.062132205814123154, -0.07909225672483444, -0.10622803866863251, 0.0024874480441212654, -0.04767609387636185, -0.0700717568397522, -0.07318663597106934, 0.0956248864531517, -0.0169319249689579, -0.048599325120449066, -0.03355983644723892, -0.09904640913009644, 0.06986209750175476, -0.09766034781932831, 0.0203403290361166, 0.04147578403353691], "changes": {"1wk": -3.4838707216324343}}, {"text": "EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors EyePoint Pharmaceuticals, Inc. Wed, Jan 8, 2025, 3:00 PM 7 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. \u201cI am pleased to welcome Dr. Sanders to EyePoint\u2019s Board,\u201d said G\u00f6ran Ando, M.D., Chair of the Board of Directors of EyePoint. \u201cScientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. Sanders will be an invaluable addition to our Board. With our global phase 3 pivotal trials for wet AMD underway and the recent positive interim data for our Phase 2 trial in diabetic macular edema, Dr. Sanders\u2019 unparalleled clinical experience and unique experience of business development in the retina space will be critical as we continue to execute across our pipeline.\u201d \u201cIt is an honor to join the EyePoint Board of Directors at this important time,\u201d said Dr. Sanders. \u201cI have dedicated my career to providing the highest quality of comprehensive care to my patients by being on the cutting-edge of innovation in retina research. I am impressed by EyePoint\u2019s robust clinical data and significant potential of DURAVYU for serious retinal diseases. The EyePoint team has a track record of excellence in execution, and I look forward to working closely with the talented management team and the Board as they continue to work to bring potential revolutionary treatments to patients.\u201d Dr. Sanders is a distinguished retina specialist currently serving as a board member of Prism Vision Group (PVG), and he is the most recent President of the American Society of Retina Specialists (ASRS). Dr. Sanders is also a physician within the Retina Group of Washington (RGW), a division of PVG. He served many years as president and managing partner of RGW and was a main driver in building RGW to become the largest practice of retinal specialists in the United States. Dr. Sanders has a career in education and research with RGW, developing a national reputation. He is well published, having more than 50 papers, articles and presentations to his credit, and has lectured nationally and abroad. Dr. Sanders has served as an investigator/sub-investigator in numerous studies of new retinal treatments, including being a principal investigator for Lucentis \u00ae , a landmark treatment for wet age-related macular degeneration (wet AMD). Story Continues Dr. Sanders has made significant contributions to ophthalmology demonstrated by a collection of honors and awards. His exceptional achievements include his election as a charter inductee into the Retina Hall of Fame, receipt of the Packo Service Award in recognition of his exceptional service to the Society. He trained at Yale-New Haven Hospital and Wills Eye Hospital in Philadelphia, and he completed a fellowship in Vitreo-retinal Diseases and Surgery at the Massachusetts Eye and Ear Infirmary/Harvard Medical School. Dr. Sanders holds an M.D. from Yale University and a B.S. from the University of Virginia. About EyePoint Pharmaceuticals EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E \u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU \u2122 (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E \u2122 . DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in\u00a0the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E \u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert \u00ae drug delivery technology has been safely administered to thousands of patient eyes across four\u00a0U.S.\u00a0FDA approved products.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the announcement of full topline data from the VERONA trial in the first quarter of 2025 and initiation of the LUGANO trial and the LUCIA trial; the belief that the interim results from the VERONA trial support DURAVYU\u2019s potential to advance to non-inferiority pivotal trials; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as \u201cwill,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cintends,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cmay,\u201d other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint\u2019s actual results to be materially different than those expressed in or implied by EyePoint\u2019s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company\u2019s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company\u2019s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company\u2019s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company\u2019s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney\u2019s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company\u2019s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Precision AQ Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2025-01-08T12:00:00+00:00", "sentiment": {"score": 0.6030600862577558, "confidence": 0.6131372451782227, "probabilities": {"positive": 0.6131372451782227, "negative": 0.0100771589204669, "neutral": 0.37678560614585876}}, "embedding": [-0.12172527611255646, -0.18110492825508118, 0.052131056785583496, -0.059568703174591064, 0.05020595341920853, -0.14699029922485352, 0.1076713502407074, 0.22715714573860168, 0.13143375515937805, 0.06631395220756531, -0.12892964482307434, 0.16039207577705383, -0.009502280503511429, 0.17563879489898682, -0.11358953267335892, 0.0036001414991915226, -0.0920049324631691, 0.009550231508910656, -0.04130977392196655, 0.08261959254741669, 0.10861892998218536, -0.04818951338529587, 0.031046975404024124, -0.052058927714824677, -0.12574481964111328, 0.021274514496326447, -0.018832486122846603, -0.12527254223823547, -0.19060666859149933, -0.15101483464241028, 0.016477545723319054, 0.004111349582672119, -0.04158111661672592, -0.04813519865274429, 0.004920838866382837, 0.09517505764961243, -0.06903232634067535, -0.00477919215336442, -0.13258486986160278, -0.0618976354598999, -0.07986851036548615, 0.011006291955709457, -0.06782574951648712, 0.12479296326637268, 0.2042202204465866, -0.13407443463802338, 0.0191092099994421, 0.062137678265571594, -0.0605953074991703, 0.07082659751176834, -0.1804177165031433, -0.14993953704833984, -0.09029295295476913, -0.04724413901567459, -0.006267125252634287, 0.16588643193244934, -0.19070753455162048, -0.1023700088262558, 0.13684861361980438, -0.07807059586048126, 0.03369669243693352, -0.04867451637983322, 0.03859398141503334, 0.07046525925397873, 0.009160538204014301, 0.007137352135032415, 0.0301982369273901, -0.0669725239276886, 0.0003940640017390251, -0.06670764088630676, 0.050810012966394424, 0.014280465431511402, 0.0220574252307415, 0.09323017299175262, 0.003143653739243746, 0.10399386286735535, 0.09396476298570633, 0.03623451292514801, 0.16179530322551727, -0.06986330449581146, 0.22893349826335907, 0.0787036344408989, 0.0841279998421669, 0.042014822363853455, 0.04533158242702484, -0.003957181237637997, -0.04140467196702957, 0.020254909992218018, -0.004809068515896797, -0.053321272134780884, 0.09936247766017914, -0.008538412861526012, -0.05201541632413864, -0.026428379118442535, -0.06794863194227219, 0.017469355836510658, -0.07456173002719879, -0.06353653967380524, -0.11930157244205475, 0.04426823928952217, -0.08770039677619934, -0.0007585799321532249, 0.008332510478794575, -0.053118519484996796, -0.049280520528554916, -0.11038509011268616, 0.08752267062664032, 0.07100576162338257, 0.008344139903783798, 0.02381952852010727, -0.030603088438510895, 0.1432403326034546, -0.05272583290934563, 0.007373419590294361, 0.004468767903745174, 0.06750571727752686, -0.09677982330322266, -0.031239034608006477, 0.24274969100952148, -0.06327496469020844, 0.053271036595106125, 0.08168666809797287, 0.024989033117890358, -0.05368676036596298, 0.11229947209358215, 0.07348036020994186, -0.03511863574385643, 3.8042560409860154e-33, -0.019235242158174515, 0.0985075831413269, 0.04420429468154907, -0.00869513675570488, 0.03627476468682289, 0.007129940669983625, 0.06929099559783936, 0.000191032188013196, -0.13705003261566162, -0.09524543583393097, -0.2511608600616455, -0.057374075055122375, 0.009059708565473557, 0.17822265625, -0.11877785623073578, -0.04458422586321831, -0.0025996193289756775, 0.0842893123626709, -0.12026742845773697, -0.01786789670586586, -0.07427128404378891, 0.13388200104236603, -0.0066153062507510185, 0.0766843780875206, 0.018917111679911613, 0.058168135583400726, -0.045138344168663025, 0.11332592368125916, 0.17596235871315002, 0.07031376659870148, -0.07806853950023651, 0.10836615413427353, 0.0006482336902990937, -0.07928061485290527, 0.06854243576526642, 0.021531887352466583, -0.0341801792383194, -0.124066561460495, 0.10969866812229156, 0.0133094172924757, -0.04197682440280914, 0.20013420283794403, -0.05447464808821678, -0.10787157714366913, 0.04139199107885361, 0.040024418383836746, -0.0086520966142416, 0.17471125721931458, -0.10098342597484589, -0.11184871196746826, -0.01129953470081091, 0.01968364417552948, 0.002584300935268402, -0.09691549837589264, 0.02060055173933506, 0.011517561972141266, -0.15949603915214539, -0.03224794566631317, 0.12645597755908966, 0.14300960302352905, 0.019249998033046722, 0.15472081303596497, -0.11696206033229828, 0.15194110572338104, -0.16493383049964905, -0.006294875405728817, 0.029964962974190712, -0.01090408768504858, -0.025027096271514893, 0.00781724788248539, 0.03768659010529518, -0.05357002466917038, 0.1032201424241066, -0.057583533227443695, -0.053397323936223984, -0.05887283384799957, 0.03220236301422119, 0.14319968223571777, -0.012448953464627266, -0.004257298074662685, -0.10013127326965332, 0.0641547217965126, -0.031678490340709686, 0.016904141753911972, 0.019290626049041748, -0.044707510620355606, 0.04397571086883545, -0.07291701436042786, -0.1122124046087265, -0.03780277445912361, 0.1510300636291504, 0.007799467071890831, -0.0021579847671091557, 0.05289267376065254, -0.0735190361738205, -5.5690528931823784e-33, -0.09622269123792648, -0.0645522028207779, 0.13229116797447205, -0.02701328508555889, 0.01616744138300419, 0.010355815291404724, 0.09219565987586975, -0.08758052438497543, 0.18078412115573883, -0.2363051474094391, 0.030900558456778526, 0.0634753406047821, -0.1837948113679886, -0.029662689194083214, -0.12208068370819092, 0.07401268929243088, -0.07159703224897385, -0.06279433518648148, -0.13400086760520935, 0.025288928300142288, 0.06623507291078568, 0.1546274721622467, 0.0008278824388980865, -0.013862858526408672, 0.04147026687860489, 0.13863399624824524, 0.1238967701792717, 0.03704186901450157, -0.06593415886163712, -0.06260401010513306, -0.04569767042994499, 0.04411114752292633, -0.22207826375961304, -0.04617616534233093, -0.0642508715391159, 0.10488393157720566, -0.05496077239513397, -0.18391908705234528, -0.028722921386361122, -0.025743048638105392, 0.2243346869945526, -0.037958379834890366, 0.02584107592701912, 0.0020667891949415207, 0.06502600014209747, 0.03859274834394455, 0.054411452263593674, 0.03924282267689705, 0.03492225706577301, -0.06684473901987076, -0.26308542490005493, -0.03961983323097229, 0.0025928225368261337, -0.01650090143084526, -0.0901336744427681, 0.0050684791058301926, 0.05412646010518074, 0.027483463287353516, 0.04303041845560074, 0.053393106907606125, 0.05708713456988335, -0.06161635369062424, 0.003724109847098589, 0.002309804782271385, 0.17342987656593323, 0.06144959479570389, 0.07503628730773926, 0.0016941707581281662, 0.05820370465517044, -0.056088678538799286, -0.01688011735677719, -0.1093335747718811, -0.17475402355194092, -0.09637658298015594, -0.012463456019759178, 0.01284494437277317, -0.13165631890296936, -0.05729241296648979, -0.17067593336105347, 0.04595167934894562, 0.008244960568845272, -0.07313714176416397, -0.06425859034061432, 0.2413610816001892, 0.025613779202103615, 0.07373432070016861, 0.10251975059509277, -0.12778586149215698, -0.03997158259153366, 0.028735194355249405, -0.16654495894908905, -0.11467602849006653, -0.05731130391359329, 0.11536294221878052, 0.061000626534223557, -1.0048511001059524e-07, 0.022264305502176285, 0.03816615790128708, 0.0434306301176548, -0.09010442346334457, -0.022304315119981766, -0.11018233001232147, -0.12464317679405212, 0.12630528211593628, -0.02756807953119278, 0.1642429083585739, 0.02617049030959606, 0.10299134254455566, -0.10097352415323257, 0.0036622919142246246, 0.08634118735790253, 0.05595381557941437, -0.026790142059326172, 0.1651555597782135, -0.1376364529132843, -0.0815805196762085, -0.02641807496547699, 0.05264074355363846, 0.053046464920043945, 0.039065223187208176, 0.023489829152822495, -0.04145994037389755, -0.020331773906946182, 0.002104833722114563, -0.019692063331604004, 0.03514367341995239, 0.08226829767227173, 0.046315599232912064, 0.12066017091274261, 0.04955329746007919, -0.03801869973540306, -0.1628725677728653, 0.014381377026438713, 0.10925252735614777, 0.05388590693473816, 0.12429706752300262, -0.1535259187221527, 0.1202256828546524, 0.11382320523262024, 0.10674271732568741, -0.11250057071447372, -0.15911133587360382, 0.06273994594812393, 0.06887999176979065, -0.05757617577910423, -0.07102654874324799, -0.052181705832481384, -0.038284093141555786, -0.08790262043476105, -0.09937351197004318, -0.10076457262039185, 0.005018324591219425, -0.006000102963298559, -0.04856981709599495, -0.12393882125616074, -0.057234782725572586, 0.05733339115977287, -0.07515043020248413, 0.039649344980716705, 0.059846095740795135], "changes": {"1wk": -20.965970575115882}}, {"text": "PREMIUM Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target MT Newswires Tue, Jan 7, 2025, 4:22 PM In This Article: EYPT -6.27% EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $33.45, accord PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2025-01-07T13:22:36+00:00", "sentiment": {"score": 0.03919174708425999, "confidence": 0.052063971757888794, "probabilities": {"positive": 0.052063971757888794, "negative": 0.012872224673628807, "neutral": 0.9350638389587402}}, "embedding": [-0.012037612497806549, -0.061204493045806885, -0.07748910784721375, 0.06842952966690063, 0.20334534347057343, 0.03699430823326111, 0.14251026511192322, 0.38017740845680237, 0.22315427660942078, 0.06930344551801682, 0.15381161868572235, -0.029086025431752205, 0.019588667899370193, -0.07188969105482101, 0.12900473177433014, -0.09631185233592987, 0.07119139283895493, -0.14311163127422333, 0.05691498890519142, -0.060001809149980545, -0.1325828731060028, -0.16204428672790527, 0.05738886445760727, 0.0003765975416172296, 0.05057830363512039, 0.040260009467601776, -0.15663620829582214, -0.09377799928188324, -0.02770981751382351, -0.13090455532073975, -0.10732204467058182, -0.06634137779474258, 0.004143471363931894, -0.013065836392343044, -0.02571486495435238, -0.06604329496622086, -0.20969827473163605, -0.10898040235042572, -0.1533563882112503, -0.04393036663532257, 0.08125674724578857, -0.0029204946476966143, -0.2987377345561981, -0.006494521163403988, 0.01787685975432396, -0.14527493715286255, -0.04750560596585274, 0.2115423083305359, -0.08014757186174393, 0.10668079555034637, -0.08697696775197983, -0.10762154310941696, 0.01312942709773779, -0.07576587051153183, -0.08962790668010712, -0.022527214139699936, -0.31015080213546753, -0.02751358039677143, 0.1640956848859787, -0.16896598041057587, 0.052755843847990036, -0.024590428918600082, -0.036400604993104935, 0.06638429313898087, -0.09536346048116684, 0.15581703186035156, 0.1115092858672142, 0.014154911041259766, 0.054145220667123795, -0.1341373175382614, -0.09180054068565369, 0.02245429903268814, 0.15099702775478363, 0.027455467730760574, 0.049673572182655334, 0.24742767214775085, 0.1026814803481102, -0.1120661050081253, -0.08113062381744385, 0.007231160532683134, 0.1427403837442398, 0.016263531520962715, -0.038017235696315765, -0.16830185055732727, 0.1709979921579361, -0.05217937007546425, 0.1931673288345337, 0.1215130090713501, 0.15129275619983673, -0.08294150233268738, 0.15182556211948395, -0.04067477583885193, -0.12644925713539124, -0.10085207968950272, -0.012595368549227715, 0.013756772503256798, -0.2668681740760803, -0.08400767296552658, -0.23840183019638062, -0.06145038828253746, 0.20500925183296204, 0.11869949847459793, -0.08968553692102432, -0.0425022654235363, -0.1774498075246811, -0.12366271764039993, 0.1556479036808014, 0.11177779734134674, 0.006685089785605669, 0.09170063585042953, -0.18737436830997467, -0.12316960841417313, -0.07384487241506577, -0.2334776222705841, -0.05072411522269249, 0.14802134037017822, -0.1784558743238449, -0.13118335604667664, 0.3077089488506317, -0.09494143724441528, 0.1294412761926651, -0.061776235699653625, -0.03131048381328583, -0.01748752035200596, -0.06663914769887924, -0.001073206658475101, -0.06210041046142578, 1.1075561405377349e-32, -0.06075456738471985, 0.19372054934501648, -0.0817035585641861, -0.2994210422039032, -0.021665863692760468, 0.08890649676322937, 0.11017942428588867, 0.07885865122079849, -0.2671714127063751, -0.11044237017631531, -0.2057582139968872, -0.08790982514619827, -0.005877145566046238, 0.18149365484714508, -0.08394354581832886, -0.06652887165546417, -0.053306203335523605, 0.17736110091209412, 0.11320638656616211, 0.0060659414157271385, -0.17834188044071198, -0.03063391149044037, -0.1134880930185318, -0.009925810620188713, -0.041550710797309875, 0.11682389676570892, -0.053455647081136703, 0.06919670850038528, 0.09997972846031189, 0.04646515101194382, -0.1922597736120224, 0.12476666271686554, 0.012534270994365215, 0.06400977820158005, 0.05252993479371071, 0.03364668786525726, -0.07227383553981781, -0.032484106719493866, 0.15695834159851074, -0.08935379236936569, 0.03892386704683304, 0.19794385135173798, 0.014094960875809193, -0.10081890225410461, 0.06615131348371506, 0.14476777613162994, -0.12972809374332428, 0.05085263028740883, 0.05220169574022293, -0.17379344999790192, -0.10315810889005661, 0.16861650347709656, -0.2707984447479248, 0.07962722331285477, -0.053718775510787964, 0.012362644076347351, -0.10464342683553696, -0.09058431535959244, 0.06372584402561188, -0.009431561455130577, 0.040717992931604385, 0.07876645028591156, 0.025721149519085884, -0.04824857786297798, -0.18600589036941528, 0.1886344999074936, -0.23311366140842438, -0.06336622685194016, -0.12047350406646729, 0.17297150194644928, 0.11741745471954346, -0.12404229491949081, 0.13618044555187225, -0.05566036328673363, 0.10140669345855713, -0.02791905775666237, -0.03642158955335617, 0.09257509559392929, 0.30550920963287354, 0.14774510264396667, -0.05010010674595833, -0.02249247021973133, 0.06307464092969894, -0.06909826397895813, 0.011568116955459118, -0.07967651635408401, -0.15086418390274048, 0.03291143476963043, -0.08635158836841583, -0.033907465636730194, 0.23019808530807495, 0.0482090562582016, -0.18562257289886475, 0.14538484811782837, -0.003517129924148321, -1.1808969963270637e-32, 0.045758191496133804, 0.12112248688936234, 0.18740424513816833, 0.004108899272978306, -0.12635913491249084, 0.08923622220754623, -0.08991575986146927, 0.09189429879188538, 0.33008459210395813, 0.2874283194541931, 0.10598945617675781, 0.003982287831604481, -0.11235056072473526, 0.045174259692430496, 0.053408022969961166, 0.0005025625578127801, 0.08933621644973755, -0.0818839818239212, 0.2020065188407898, -0.029698576778173447, 0.018396779894828796, -0.06740273535251617, -0.01873861253261566, 0.19767123460769653, 0.10243698209524155, 0.09079986810684204, 0.21700605750083923, -0.016736691817641258, 0.055688876658678055, -0.15312568843364716, -0.09416568279266357, -0.025102710351347923, -0.22687439620494843, 0.09093759208917618, -0.13562962412834167, 0.04045420140028, 0.1281183511018753, -0.027135899290442467, -0.05328846722841263, -0.07434463500976562, 0.08864043653011322, -0.12227906286716461, 0.07792837917804718, -0.023809505626559258, 0.15894657373428345, -0.062167104333639145, 0.19858688116073608, 0.031008221209049225, 0.04618040844798088, -0.054287463426589966, -0.04103682562708855, 0.08900099247694016, 0.05134199559688568, 0.11596418917179108, -0.28826144337654114, 0.1502208411693573, 0.03604316711425781, 0.11666155606508255, -0.05826412886381149, -0.1041739210486412, 0.18844960629940033, 0.22653155028820038, -0.16721445322036743, -0.012236831709742546, 0.022315749898552895, -0.057221077382564545, 0.12267395853996277, 0.013774402439594269, 0.0880037397146225, -0.021026520058512688, 0.008810244500637054, -0.12510636448860168, 0.020376943051815033, -0.23362842202186584, -0.011414183303713799, 0.10751120746135712, 0.06603676080703735, -0.04754748195409775, 0.029421014711260796, -0.06846387684345245, 0.1486508548259735, -0.0897725522518158, 0.04644009470939636, 0.02278369478881359, -0.13727180659770966, -0.020185498520731926, 0.09317769855260849, -0.052195750176906586, -0.14399734139442444, 0.24547803401947021, -0.21327577531337738, -0.08575889468193054, -0.03594013303518295, 0.15889061987400055, 0.12431338429450989, -9.984371729387931e-08, 0.0001098685315810144, -0.06628132611513138, -0.013023944571614265, 0.09528490155935287, 0.017611641436815262, -0.10842663049697876, 0.020241718739271164, 0.12154623121023178, -0.10291621834039688, 0.15249277651309967, -0.0855225920677185, -0.11946376413106918, -0.06679097563028336, 0.12262238562107086, -0.06005047261714935, -0.044005684554576874, 0.0040215663611888885, 0.15200850367546082, 0.004926205612719059, -0.06813938170671463, -0.02646399289369583, 0.08520451188087463, 0.20576977729797363, -0.1416902095079422, -0.049403320997953415, 0.13881419599056244, 0.03666331246495247, 0.10047377645969391, 0.05283012613654137, 0.10176300257444382, -0.04186141863465309, -0.0007197038503363729, 0.04578208923339844, -0.0551614910364151, 0.014789373613893986, -0.13956673443317413, -0.03015408292412758, 0.059721365571022034, -0.02117214724421501, 0.03542376309633255, -0.029700832441449165, 0.024909887462854385, 0.011559688486158848, 0.05156519636511803, 0.00908337440341711, -0.025908974930644035, -0.17820727825164795, -0.16329075396060944, 0.0898715928196907, -0.14634539186954498, 0.08572761714458466, 0.0090801902115345, -0.07768815010786057, -0.0033152627293020487, 0.02272818051278591, -0.18224088847637177, -0.08421356230974197, -0.09650241583585739, -0.0971347913146019, 0.0628380998969078, 0.09472698718309402, -0.32179662585258484, 0.02566029503941536, 0.16311641037464142], "changes": {"1wk": -15.943603302112741}}, {"text": "EyePoint reports inducement grants under NASDAQ listing rule TipRanks Tue, Dec 17, 2024, 3:25 PM 1 min read In This Article: EYPT -6.27% https://www.tipranks.com/news/the-fly/ovid-therapeutics-upgraded-at-oppenheimer-as-ov329s-promise-quite-real EyePoint ( EYPT ) announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 54,600 shares of EyePoint Pharmaceuticals common stock to six new employees. The stock options were granted on December 13, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.46 per share, the closing price of EyePoint Pharmaceuticals\u2019 common stock on December 13, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee\u2019s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee\u2019s continued service with EyePoint Pharmaceuticals through the applicable vesting dates. Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today\u2019s best-performing stocks on TipRanks >> Read More on EYPT: EyePoint doses first patient in second Phase 3 LUCIA clinical trial EyePoint reports inducement grants under NASDAQ listing rule EyePoint price target lowered to $22 from $30 at H.C. Wainwright EyePoint price target lowered to $33 from $38 at Baird EyePoint Pharmaceuticals Advances in Retinal Therapeutics View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-12-17T12:25:29+00:00", "sentiment": {"score": 0.038396816700696945, "confidence": 0.06265879422426224, "probabilities": {"positive": 0.06265879422426224, "negative": 0.024261977523565292, "neutral": 0.9130792617797852}}, "embedding": [-0.11042382568120956, -0.06791799515485764, 0.01720922440290451, -0.02455078437924385, -0.029377421364188194, 0.06480763107538223, 0.13942596316337585, 0.2077224999666214, 0.06336245685815811, 0.06290039420127869, 0.018939172849059105, 0.17048808932304382, -0.0069724190980196, 0.08222150802612305, -0.07637818157672882, 0.04738781601190567, 0.013889129273593426, -0.0641380175948143, -0.06699744611978531, 0.027234742417931557, 0.021733181551098824, -0.14038726687431335, -0.00087921810336411, -0.10785316675901413, 0.03227793052792549, 0.0014634229009971023, -0.0710257962346077, 0.029608838260173798, -0.14421483874320984, -0.07665952295064926, -0.015352535992860794, 0.06226092576980591, 0.004739424679428339, -0.11057902127504349, -0.09471993893384933, -0.03283439949154854, -0.13062705099582672, 0.05359911918640137, -0.019969170913100243, 0.020061085000634193, -0.048110950738191605, -0.05307571962475777, -0.10861941426992416, 0.060279056429862976, 0.043050576001405716, -0.13061007857322693, 0.01085930410772562, 0.03826174512505531, -0.0019648883026093245, 0.05557524785399437, -0.18091951310634613, -0.020349394530057907, -0.04113885760307312, 0.048937730491161346, -0.09744101017713547, -0.01911819912493229, -0.19320936501026154, -0.025437626987695694, 0.03378461301326752, 0.03603671118617058, -0.025143783539533615, -0.012920541688799858, 0.03891979157924652, 0.013667904771864414, 0.09857045114040375, 0.02187723107635975, 0.06992591917514801, -0.04059721529483795, 0.02269699238240719, -0.020357899367809296, 0.02054383046925068, 0.004932102747261524, -0.02664286084473133, -0.0647091493010521, -0.07303967326879501, 0.22528395056724548, 0.13270246982574463, 0.019923711195588112, 0.09581708908081055, -0.15765950083732605, 0.03369612991809845, 0.018905745819211006, -0.018409041687846184, -0.021490542218089104, 0.004323773551732302, -0.10708241909742355, 0.012101943604648113, 0.049183666706085205, 0.18913665413856506, 0.07121557742357254, 0.10002414882183075, -0.07106298208236694, -0.11183036863803864, -0.14343485236167908, 0.050981827080249786, -0.08921461552381516, -0.14809846878051758, -0.08178217709064484, -0.1102643609046936, 0.024167485535144806, 0.08702453970909119, -0.05661354959011078, -0.10819083452224731, -0.05866743251681328, -0.006480618380010128, -0.053978778421878815, 0.08092464506626129, -0.04017484560608864, 0.029179012402892113, 0.02909025549888611, -0.11411869525909424, 0.08258907496929169, -0.016810346394777298, -0.09813498705625534, -0.14903876185417175, 0.1855086386203766, -0.09762223064899445, -0.06514936685562134, 0.21868965029716492, -0.022827519103884697, 0.10994602739810944, 0.10146531462669373, 0.05315132439136505, -0.08534234762191772, -0.031207740306854248, -0.015909915789961815, -0.15205606818199158, 1.3386845581270994e-32, 0.0006903751054778695, 0.06193620339035988, 0.03087043948471546, -0.0972239151597023, -0.0153423510491848, -0.008786444552242756, 0.07613247632980347, 0.05964392051100731, -0.2204420566558838, 0.05444043502211571, -0.20121000707149506, -0.0005664283526130021, 0.029486089944839478, 0.04748303070664406, 0.05941404029726982, -0.0344868004322052, -0.01716768927872181, 0.1883535236120224, -0.007360661402344704, 0.0019915872253477573, 0.03939781337976456, -0.0036370200105011463, -0.09504172205924988, 0.02050156518816948, 0.05601906776428223, 0.0408681221306324, -0.10789656639099121, -0.020717807114124298, -0.04047780856490135, 0.04229869320988655, -0.016443148255348206, 0.07711423933506012, 0.042162973433732986, -0.07969068735837936, 0.050870247185230255, -0.10237089544534683, -0.05806775391101837, -0.09497363120317459, 0.1622048020362854, -0.08854038268327713, 0.023936353623867035, 0.12982171773910522, 0.006505493074655533, -0.07021596282720566, -0.005675830412656069, 0.1190083846449852, -0.06312357634305954, 0.1244245171546936, -0.008801891468465328, 0.0416644886136055, -0.047356557101011276, 0.017955223098397255, -0.04830309748649597, -0.0388624481856823, -0.09660447388887405, 0.06629348546266556, -0.12828630208969116, -0.035232026129961014, 0.09725306928157806, 0.08071355521678925, 0.039718035608530045, 0.13859246671199799, -0.04698074236512184, 0.022701065987348557, -0.20419971644878387, 0.07028455287218094, -0.028151175007224083, -0.05059709772467613, 0.0029471360612660646, 0.1631583571434021, -0.012488395906984806, -0.006229338701814413, 0.20599427819252014, -0.11527204513549805, 0.05452430248260498, -0.07650642096996307, 0.05129015073180199, 0.06990477442741394, 0.13397452235221863, -0.043153125792741776, 0.057198747992515564, -0.04587762430310249, -0.011247998103499413, 0.013468167744576931, 0.07545116543769836, -0.02759305201470852, 0.008317082189023495, -0.018329693004488945, -0.09387356787919998, -0.01772620528936386, 0.10966750234365463, -0.020978406071662903, -0.08010230213403702, 0.057927265763282776, 0.014625482261180878, -1.1379095352594772e-32, -0.062183644622564316, -0.008183066733181477, 0.034384824335575104, -0.05522060766816139, 0.0003296589129604399, 0.09106463938951492, 0.07865104079246521, -0.045061640441417694, 0.05301976948976517, 0.0035046853590756655, 0.010490932501852512, 0.055345360189676285, -0.007618006318807602, -0.012922353111207485, -0.08720579743385315, 0.011788145639002323, -0.09251270443201065, -0.05477859452366829, -0.03561748191714287, -0.00855345744639635, 0.04734458774328232, 0.11839635670185089, -0.10099801421165466, 0.1589459925889969, 0.12506471574306488, 0.08409341424703598, 0.10026136785745621, 0.04799627885222435, 0.04742796719074249, 0.020573392510414124, -0.14699208736419678, -0.0010016566375270486, -0.30027779936790466, 0.12376657128334045, 0.01356614287942648, -0.03280653432011604, 0.10734441876411438, -0.19783948361873627, -0.024719640612602234, 0.05259479582309723, 0.13482671976089478, -0.05751200392842293, 0.09610661119222641, 0.0655219629406929, 0.05050034821033478, -0.004926634952425957, 0.015324012376368046, -0.023954614996910095, 0.10203061252832413, -0.04510905221104622, -0.11459614336490631, -0.027721576392650604, 0.03129912167787552, 0.1408243030309677, -0.09220472723245621, -0.0008306097006425261, 0.036594096571207047, -0.023525923490524292, 0.026544179767370224, -0.028305048123002052, 0.11776506155729294, 0.06840086728334427, -0.047048356384038925, -0.012065350078046322, 0.0895572304725647, -0.08531560003757477, 0.05097201466560364, -0.0014381154906004667, -0.060861799865961075, -0.10453689843416214, -0.032419439405202866, -0.14667336642742157, 0.15270964801311493, -0.16669411957263947, 0.0857190489768982, 0.19120880961418152, 0.08273269981145859, -0.09893972426652908, -0.0956035703420639, -0.0010238845134153962, 0.020756812766194344, -0.04716344550251961, 0.05088767409324646, 0.11663646250963211, 0.007272141985595226, 0.11711625009775162, 0.0996752679347992, 0.021006280556321144, -0.027733713388442993, 0.044746577739715576, -0.14983168244361877, -0.13104204833507538, -0.0302923284471035, 0.09011229872703552, -0.015204683877527714, -1.0007538975287389e-07, -0.03912004455924034, -0.016864215955138206, 0.015436592511832714, 0.005203913897275925, 0.09901547431945801, -0.04172036051750183, 0.00266452063806355, 0.15832756459712982, 0.012863315641880035, 0.06932002305984497, 0.13416391611099243, 0.12212424725294113, -0.10281593352556229, 0.04855971783399582, -0.01817607507109642, -0.06111012026667595, -0.11044743657112122, 0.0243678018450737, -0.0850018560886383, -0.11696401983499527, -0.10572642087936401, 0.016595730558037758, 0.04722697660326958, -0.05972162261605263, -0.04375597462058067, 0.01688431203365326, 0.037748247385025024, 0.10310899466276169, 0.04036065563559532, 0.1132500171661377, 0.06576251983642578, -0.010891390033066273, 0.09059653431177139, -0.00996908824890852, -0.04124119505286217, -0.04707276076078415, 0.054498299956321716, 0.12315163016319275, 0.010929478332400322, 0.14506128430366516, -0.09066697955131531, 0.00011721972987288609, 0.025892069563269615, 0.033239398151636124, 0.03840893879532814, -0.005853064823895693, -0.21508127450942993, -0.03630468249320984, 0.010425898246467113, -0.11635973304510117, 0.07436062395572662, -0.030118683353066444, -0.08335314691066742, 0.022814767435193062, 0.06775377690792084, -0.03909827768802643, -0.058061182498931885, -0.10802899301052094, -0.09994915127754211, -0.020471127703785896, 0.08286038041114807, -0.15661311149597168, -0.010467112995684147, 0.15625371038913727], "changes": {"1wk": -9.601002666007101, "1mo": -4.114717976403102}}, {"text": "EyePoint doses first patient in second Phase 3 LUCIA clinical trial TipRanks Thu, Dec 5, 2024, 3:06 PM 1 min read In This Article: EYPT -6.27% https://www.tipranks.com/news/the-fly/mind-medicine-doses-first-patient-in-panorama-study EyePoint ( EYPT ) Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial, the Company\u2019s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E(TM) for sustained intraocular delivery. LUGANO and LUCIA are global, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including treatment naive and treatment experienced patients. Each trial is expected to enroll approximately 400 patients globally who will be randomly assigned to a 2.7mg dose of DURAVYU or an on-label aflibercept control. The LUGANO and LUCIA trials are the only sustained release wet AMD pivotal Phase 3 trials evaluating re-dosing in both trials. Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial. DURAVYU is delivered via a standard intravitreal injection in the physician\u2019s office, similar to current standard practice with FDA approved anti-VEGF treatments. The primary endpoint of the Phase 3 pivotal trials is the average change in best corrected visual acuity at weeks 52 and 56 versus baseline. Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections and anatomical results as measured by optical coherence tomography. Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on EYPT: EyePoint reports inducement grants under NASDAQ listing rule EyePoint price target lowered to $22 from $30 at H.C. Wainwright EyePoint price target lowered to $33 from $38 at Baird EyePoint Pharmaceuticals Advances in Retinal Therapeutics EyePoint reports Q3 EPS (54c), consensus (55c) View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-12-05T12:06:44+00:00", "sentiment": {"score": 0.12409330904483795, "confidence": 0.1350606083869934, "probabilities": {"positive": 0.1350606083869934, "negative": 0.010967299342155457, "neutral": 0.8539720773696899}}, "embedding": [0.022259585559368134, -0.08940765261650085, 0.02294343151152134, -0.04077719524502754, 0.0003834263188764453, -0.14653638005256653, -0.02930154837667942, 0.22816750407218933, 0.05983637645840645, 0.11847478151321411, 0.030739326030015945, 0.04924717918038368, -0.023949982598423958, 0.057756632566452026, -0.05521107465028763, 0.0625981017947197, 0.007440177723765373, -0.014549974352121353, -0.028758637607097626, 0.161300927400589, 0.1326640248298645, -0.0939430296421051, 0.00341019406914711, 0.049834489822387695, -0.10520704090595245, 0.015995196998119354, -0.08038156479597092, 0.006405236665159464, -0.08460802584886551, -0.1739511638879776, 0.022762712091207504, 0.16074252128601074, -0.08297339826822281, -0.11931510269641876, -0.023790769279003143, -0.06063707545399666, -0.2212119698524475, -0.06151502579450607, -0.15461470186710358, 0.02531336061656475, -0.027206288650631905, -0.06290611624717712, -0.18205201625823975, 0.06694819778203964, 0.07541988790035248, -0.15771633386611938, -0.10458765178918839, 0.11473644524812698, -0.0061513762921094894, 0.1739712804555893, -0.13073360919952393, -0.12218567728996277, -0.05668988823890686, 0.1787751019001007, -0.0415671244263649, -0.012971777468919754, -0.1612580269575119, 0.045964695513248444, 0.10153226554393768, -0.007462172769010067, -0.006766662001609802, 0.0008432557806372643, -0.0012394767254590988, 0.010277673602104187, 0.00107673741877079, 0.0421891063451767, 0.051752910017967224, -0.12624810636043549, -0.013930413872003555, 0.005855413153767586, 0.02618568390607834, -0.01863735541701317, 0.0816449299454689, -0.002567949704825878, -0.006168175023049116, 0.12195625901222229, 0.05181339383125305, -0.06477554142475128, 0.02646745927631855, -0.04420097917318344, 0.0554201677441597, 0.08660770207643509, 0.014528601430356503, 0.028604930266737938, 0.09673670679330826, -0.05301528424024582, -0.04400425776839256, 0.03470717370510101, 0.03999466449022293, -0.033881776034832, 0.1563975214958191, 0.07887048274278641, -0.08885984122753143, -0.011725588701665401, 0.12679645419120789, -0.02311921864748001, -0.11901155859231949, 0.012704000808298588, -0.1021188348531723, 0.03496208041906357, 0.029669659212231636, -0.0986783355474472, -0.01780962385237217, 0.018771454691886902, 0.007194800302386284, -0.023158526048064232, 0.17617179453372955, -0.16779163479804993, -0.005852631293237209, -0.0240650475025177, -0.0793483778834343, 0.06448175758123398, 0.05843359977006912, 0.04680084437131882, -0.0587199367582798, 0.18925926089286804, -0.05797208845615387, 0.04817808419466019, 0.3741874694824219, -0.013079667463898659, 0.15753616392612457, 0.0027639258187264204, 0.08170773088932037, -0.12022219598293304, 0.13275010883808136, 0.031225213780999184, 0.014571829698979855, 1.4545490689942182e-32, 0.016231954097747803, -0.01684279553592205, -0.10403136909008026, 0.011393941938877106, -0.024080360308289528, -0.04418115317821503, 0.010194724425673485, 0.018614938482642174, -0.18422052264213562, -0.11087165027856827, -0.21346917748451233, -0.012667808681726456, -0.02095900848507881, 0.21338114142417908, -0.06521477550268173, -0.11745023727416992, 0.0686836689710617, 0.16576771438121796, -0.07619675993919373, 0.07821563631296158, 0.05815688520669937, 0.004323541186749935, -0.10848671197891235, 0.03385984152555466, -0.07508677989244461, 0.15426382422447205, -0.08279509097337723, 0.04550384730100632, 0.031491272151470184, 0.11759178340435028, -0.1039215624332428, 0.09587708115577698, -0.0036573829129338264, -0.11623233556747437, -0.08090278506278992, 0.014746762812137604, -0.028113413602113724, -0.08906085789203644, -0.024808671325445175, 0.06604115664958954, -0.01411639153957367, 0.1315179318189621, -0.024711033329367638, -0.09578211605548859, 0.04687787964940071, -0.0662030428647995, -0.09279190003871918, 0.0523485504090786, 0.013711284846067429, -0.05942545458674431, -0.03259681537747383, -0.11200107634067535, -0.05777885764837265, -0.1392669379711151, 0.035215288400650024, 0.13568969070911407, -0.18063771724700928, -0.006456379313021898, 0.10129091143608093, 0.06442838907241821, 0.05559912323951721, 0.037153471261262894, -0.05357089638710022, 0.08395138382911682, -0.051802635192871094, 0.011428795754909515, 0.006695156916975975, -0.04747416824102402, -0.08830071985721588, -0.1339944452047348, -0.06002894416451454, -0.025621915236115456, 0.14141379296779633, 0.056361887603998184, 0.02745962142944336, -0.01785355433821678, 0.12871506810188293, 0.1842038631439209, 0.051397860050201416, -0.052895404398441315, 0.001945724943652749, -0.025920644402503967, -0.0910712257027626, 0.032008096575737, -0.013724683783948421, -0.020431265234947205, 0.05691881105303764, -0.009427003562450409, -0.196673184633255, -0.046505920588970184, 0.1503736972808838, 0.005738858599215746, -0.025760889053344727, -0.06504064798355103, 0.030711233615875244, -1.2693340648484307e-32, -0.07507751882076263, -0.019903868436813354, 0.06910981237888336, 0.06820710003376007, -0.04561479389667511, 0.15833280980587006, 0.12238636612892151, -0.06302110105752945, 0.10135418176651001, -0.20072072744369507, -0.04816427081823349, 0.010894129052758217, -0.07963920384645462, -0.12774725258350372, -0.06347054243087769, 0.0726945772767067, -0.08103442192077637, -0.04349277913570404, -0.1249975711107254, 0.019027963280677795, 0.1210000142455101, 0.04840818792581558, -0.020300928503274918, 0.011793762445449829, 0.10056151449680328, 0.04862457513809204, 0.11169310659170151, 0.04648114740848541, -0.07223622500896454, -0.01957639493048191, -0.14149123430252075, 0.056441280990839005, -0.22647488117218018, 0.029454320669174194, -0.0789390429854393, 0.10593355447053909, 0.008232945576310158, -0.16404840350151062, -0.10268163681030273, -0.007587458938360214, 0.11686982214450836, -0.052251946181058884, 0.039279013872146606, -0.09060120582580566, 0.012816819362342358, 0.09235193580389023, 0.044294849038124084, 0.0005481187254190445, 0.16491873562335968, -0.017392579466104507, -0.08915166556835175, 0.037615641951560974, -0.008394906297326088, 0.06728675216436386, 0.016484616324305534, -0.1358187049627304, 0.07203951478004456, -0.055152423679828644, -0.08589371293783188, 0.04046650230884552, 0.06333385407924652, 0.009484975598752499, -0.05267859995365143, -0.016509581357240677, 0.11366090923547745, 0.16285279393196106, 0.07075026631355286, 0.04589330404996872, 0.11581368744373322, -0.015624277293682098, -0.0009583025239408016, -0.04015802592039108, -0.07807686924934387, -0.19702577590942383, 0.04364614561200142, 0.16701051592826843, -0.010489233769476414, -0.1390148103237152, -0.13890504837036133, -0.07439761608839035, -0.020699307322502136, -0.11319037526845932, -0.030274946242570877, 0.09988772869110107, -0.04732879251241684, 0.0693998783826828, 0.09392651915550232, -0.17375245690345764, -0.028377529233694077, 0.05076201260089874, -0.16856694221496582, -0.08868864923715591, -0.13921886682510376, 0.10317109525203705, 0.09401977062225342, -1.0051142140810043e-07, 0.023993350565433502, 0.018107237294316292, 0.03435250744223595, -0.02424423024058342, 0.09398157894611359, -0.1616235077381134, -0.07491111755371094, 0.12952832877635956, -0.10869787633419037, 0.0803634375333786, 0.007360910996794701, 0.07922855019569397, 0.04754415526986122, -0.03291965648531914, 0.13082599639892578, 0.0402502566576004, 0.12509091198444366, 0.11766829341650009, -0.08724101632833481, -0.04076175019145012, -0.03687204420566559, 0.009479721076786518, 0.11930891871452332, -0.1593858301639557, 0.004875883460044861, 0.05295094475150108, 0.036596667021512985, 0.11542585492134094, 0.09602106362581253, -0.042836885899305344, 0.10160116851329803, 0.015517162159085274, 0.051135871559381485, -0.03500796854496002, -0.07367002218961716, -0.06097547709941864, -0.008786775171756744, 0.13597950339317322, 0.0602683499455452, 0.13679465651512146, -0.06425878405570984, 0.01895711198449135, 0.06421136856079102, 0.007707301527261734, -0.012808285653591156, -0.013807316310703754, -0.023328740149736404, -0.01589532196521759, -0.05692211166024208, -0.10947419703006744, -0.0157772209495306, 0.0394296832382679, -0.01662617176771164, 0.024150758981704712, -0.07453671097755432, 0.10915828496217728, 0.0854288637638092, -0.012929550372064114, -0.010149875655770302, -0.08387574553489685, 0.038684166967868805, -0.030392425134778023, -0.01822841539978981, 0.022262699902057648], "changes": {"1wk": 1.1029430670447082, "1mo": 1.2254948938686687}}, {"text": "EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 4:35 PM 3 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.55 per share when it actually produced a loss of $0.58, delivering a surprise of -5.45%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. EyePoint Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $10.52 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 14.79%. This compares to year-ago revenues of $15.2 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. EyePoint Pharmaceuticals shares have lost about 47.7% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for EyePoint Pharmaceuticals? While EyePoint Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for EyePoint Pharmaceuticals: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.48 on $12.35 million in revenues for the coming quarter and -$2.29 on $46.57 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Atyr Pharma (ATYR), is yet to report results for the quarter ended September 2024. This biotherapeutics company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -10%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Atyr Pharma's revenues are expected to be $0.13 million, down 62.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report aTyr Pharma, Inc. (ATYR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-11-07T13:35:06+00:00", "sentiment": {"score": -0.646023865789175, "confidence": 0.704066812992096, "probabilities": {"positive": 0.058042947202920914, "negative": 0.704066812992096, "neutral": 0.2378903180360794}}, "embedding": [-0.09964939951896667, -0.03194836154580116, 0.014975315891206264, 0.0399310365319252, 0.02832721546292305, -0.015317647717893124, 0.029710782691836357, 0.25757673382759094, 0.2383495271205902, 0.11214125156402588, -0.06979874521493912, 0.1498757004737854, 0.007206834852695465, -0.004289626609534025, -0.10362143069505692, -0.040029510855674744, 0.010397655889391899, -0.054207928478717804, -0.046215228736400604, 0.02881055697798729, 0.0036489719059318304, -0.047589998692274094, 0.1533932238817215, 0.03728589788079262, 0.06592109054327011, 0.12270934879779816, -0.12522977590560913, 0.027306653559207916, -0.20800656080245972, -0.13062065839767456, -0.05561494082212448, 0.06256423890590668, 0.06742274016141891, -0.06692641228437424, -0.06283532083034515, -0.055436789989471436, -0.043615248054265976, 0.06095704436302185, 0.09722691774368286, -0.02980627864599228, -0.0905890166759491, 0.003945646807551384, -0.20045198500156403, 0.0016504209488630295, 0.01194126345217228, -0.22412672638893127, -0.041243117302656174, -0.021808074787259102, -0.04926135390996933, 0.08465982973575592, -0.19905985891819, -0.09803152829408646, 0.02803768962621689, 0.04786290228366852, -0.10801750421524048, 0.051582593470811844, -0.13517653942108154, -0.06738229095935822, 0.0721847265958786, 0.06519632786512375, 0.05365942418575287, 0.041327036917209625, 0.02707754261791706, 0.03395402804017067, 0.13321217894554138, 0.03226582705974579, 0.14186984300613403, 0.02106301672756672, -0.04650689288973808, 0.03159284219145775, 0.02584071457386017, -0.009973804466426373, -0.039408907294273376, -0.00920498464256525, -0.12125232815742493, 0.09049475193023682, 0.1525833010673523, 0.07772131264209747, 0.029556499794125557, -0.025989186018705368, 0.15912839770317078, -0.014969740062952042, -0.0927819237112999, -0.033409811556339264, 0.027091963216662407, -0.04282611608505249, 0.15064013004302979, 0.13454578816890717, 0.08105797320604324, 0.042540293186903, -0.02466254122555256, -0.045951735228300095, -0.07497300207614899, -0.08409503847360611, 0.10360637307167053, 0.0010776231065392494, -0.15339481830596924, -0.1344558447599411, -0.02502034790813923, 0.01892939954996109, 0.1252610832452774, 0.14278316497802734, -0.04136833921074867, -0.15367361903190613, 0.0387146957218647, -0.08537174761295319, 0.13141877949237823, -0.0196908637881279, 0.05620504543185234, 0.09528541564941406, -0.08065461367368698, 0.055200301110744476, -0.16901367902755737, -0.0513872429728508, -0.04041142761707306, 0.10779096186161041, -0.07162617892026901, 0.059986963868141174, 0.10770006477832794, 0.12719792127609253, 0.0816393792629242, 0.11793391406536102, 0.05203141272068024, -0.048582449555397034, 0.031768836081027985, 0.05063170939683914, -0.14757882058620453, 7.749757279114929e-33, 0.09058574587106705, 0.12166698276996613, -0.004933914169669151, -0.11973889917135239, -0.03996884077787399, 0.0761086642742157, 0.05856882780790329, 0.029807591810822487, -0.07729782164096832, -0.13296669721603394, -0.18591314554214478, -0.012372400611639023, -0.02396301180124283, -0.0008274414576590061, -0.003972511738538742, -0.09095855802297592, -0.0369841568171978, 0.14064240455627441, 0.03810218721628189, -0.036090247333049774, -0.0973430871963501, -0.06306678801774979, -0.09821674227714539, 0.01663327030837536, -0.01017333846539259, 0.07229458540678024, -0.12185929715633392, 0.1145603358745575, -0.1284843236207962, 0.027985654771327972, -0.05089710280299187, 0.04013248160481453, 0.058127954602241516, -0.10917013883590698, -0.014469549059867859, -0.09748482704162598, -0.006965678185224533, -0.02639416791498661, 0.2558453679084778, 0.03580393269658089, -0.0873975157737732, 0.14534208178520203, -0.10687559098005295, -0.1340758204460144, -0.06851570308208466, 0.05614589899778366, -0.05591171979904175, 0.07421597093343735, -0.0206490196287632, -0.0426296666264534, -0.02221161685883999, 0.028591422364115715, -0.05073940381407738, -0.030588136985898018, -0.03774875029921532, 0.07648342847824097, -0.0713202953338623, -0.21441033482551575, 0.061239637434482574, 0.12121910601854324, 0.10473895072937012, 0.24757367372512817, 0.02390444464981556, -0.0435774102807045, -0.21386095881462097, 0.17368406057357788, 0.011073541827499866, 0.04544098302721977, -0.1298532485961914, 0.27094003558158875, -0.03113587573170662, -0.07895170897245407, 0.152596116065979, -0.05389292538166046, 0.18053892254829407, -0.04394302889704704, -0.033048417419195175, 0.01850942149758339, 0.14817848801612854, 0.054168712347745895, 0.04867532104253769, -0.07452893257141113, -1.131114549934864e-05, -0.026709340512752533, -0.01929759979248047, -0.04165046662092209, 0.06029447913169861, 0.028806153684854507, -0.033576153218746185, -0.022568751126527786, 0.08210279792547226, -0.15123561024665833, -0.13256022334098816, 0.09626951813697815, -0.011217538267374039, -7.4460991703067e-33, -0.05974198132753372, 0.11819915473461151, -0.004659357480704784, 0.005956456530839205, -0.13127103447914124, -0.015467877499759197, 0.09706776589155197, 0.08955449610948563, 0.08679348230361938, 0.027001984417438507, 0.02453766204416752, -0.008585304021835327, -0.1573610007762909, 0.028980962932109833, -0.05731566250324249, 0.02494392916560173, 0.07362230867147446, -0.19717273116111755, 0.07920128107070923, -0.04570207744836807, 0.10182438045740128, 0.12274953722953796, -0.10833466053009033, 0.09852014482021332, 0.05573635175824165, 0.08838436752557755, 0.059730030596256256, 0.10518422722816467, 0.0024730470031499863, -0.11186714470386505, -0.009001308120787144, -0.09873691201210022, -0.16196605563163757, 0.09126999229192734, -0.004897973034530878, 0.02320237085223198, -0.06408921629190445, -0.1824406385421753, -0.029476024210453033, -0.08472190797328949, 0.19069097936153412, -0.022747913375496864, 0.06410133093595505, 0.021430669352412224, 0.06656737625598907, 0.04240540415048599, 0.06079741567373276, 0.07467611134052277, 0.19277100265026093, 0.021690430119633675, -0.03000490739941597, 0.0593472421169281, -0.12015300989151001, 0.14643733203411102, -0.16964292526245117, 0.06360843032598495, -0.07603032886981964, -0.0019068261608481407, -0.15254035592079163, -0.0032331598922610283, 0.030870560556650162, 0.10758686065673828, -0.031502120196819305, 0.05129591003060341, 0.031329263001680374, -0.006031074561178684, 0.06629177927970886, -0.04148653894662857, 0.09822279214859009, -0.1083436980843544, 0.06476695835590363, -0.09629374742507935, 0.14138460159301758, -0.15208745002746582, 0.046261753886938095, 0.27906692028045654, -0.07337219268083572, -0.18277792632579803, -0.11396738141775131, -0.03619436174631119, 0.19036193192005157, 0.04636164382100105, 0.05289251357316971, -0.011471493169665337, -0.1510060727596283, 0.15487296879291534, 0.027996614575386047, -0.01355956681072712, -0.07604406774044037, 0.026961518451571465, -0.0905957967042923, -0.16811388731002808, -0.1686599850654602, 0.0661294013261795, 0.12889093160629272, -9.978666071219777e-08, 0.01832452602684498, -0.06960853934288025, 0.0804806798696518, 0.028075851500034332, 0.09025798738002777, -0.10385145992040634, 0.09191173315048218, 0.058931734412908554, 0.10562854260206223, 0.09849725663661957, 0.014891707338392735, 0.011139430105686188, -0.22804316878318787, 0.10638853907585144, -0.09275113791227341, -0.004094507545232773, -0.10563033074140549, 0.054845064878463745, -0.027836300432682037, -0.17121393978595734, -0.141558438539505, 0.05126681551337242, 0.09641583263874054, -0.15472039580345154, 0.050759706646203995, -0.027933822944760323, -0.07554201781749725, 0.013328935950994492, -0.009609420783817768, 0.012768086045980453, 0.13960570096969604, -0.057596154510974884, 0.07298770546913147, 0.07106712460517883, -0.05932587385177612, -0.1629379242658615, 0.05530267208814621, 0.07906001806259155, 0.05145580321550369, 0.1256982535123825, -0.08401456475257874, 0.005077920388430357, -0.0063789160922169685, 0.07529446482658386, -0.0526549331843853, -0.09807951003313065, -0.10940194129943848, 0.035351093858480453, 0.006206721067428589, -0.26250016689300537, 0.12831233441829681, -0.07673028111457825, -0.013363807462155819, -0.028767257928848267, 0.0890442430973053, 0.0018940567970275879, -0.151597261428833, -0.07199400663375854, -0.1802915334701538, -0.04999063163995743, 0.06705224514007568, -0.2588566541671753, 0.05666177719831467, 0.156515970826149], "changes": {"1wk": -7.161345235364185, "1mo": -24.849008425576706}}, {"text": "Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? Zacks Equity Research Wed, Nov 13, 2024, 5:55 PM 4 min read In This Article: EYPT -6.27% Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.56 indicates a potential upside of 175.1%. The average comprises nine short-term price targets ranging from a low of $18 to a high of $68, with a standard deviation of $15.13. While the lowest estimate indicates an increase of 62% from the current price level, the most optimistic estimate points to a 512.1% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. However, an impressive consensus price target is not the only factor that indicates a potential upside in EYPT. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts. However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces. Story Continues That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Here's Why There Could be Plenty of Upside Left in EYPT Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 5.5%, as three estimates have moved higher compared to no negative revision. Moreover, EYPT currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much EYPT could gain, the direction of price movement it implies does appear to be a good guide. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-11-13T14:55:10+00:00", "sentiment": {"score": 0.08814579993486404, "confidence": 0.12405899167060852, "probabilities": {"positive": 0.12405899167060852, "negative": 0.035913191735744476, "neutral": 0.8400278687477112}}, "embedding": [0.013541105203330517, -0.0025440386962145567, 0.012160946615040302, 0.108635812997818, 0.03349033743143082, -0.002757756505161524, -0.015134181827306747, 0.1998770833015442, 0.1751231849193573, -0.012812483124434948, -0.1356780230998993, 0.050481729209423065, 0.036297522485256195, -0.054305657744407654, 0.006064017303287983, -0.053242556750774384, 0.12658993899822235, -0.06157434359192848, -0.11866327375173569, 0.14499399065971375, -0.1339782476425171, -0.11047017574310303, -0.011074541136622429, 0.01645888015627861, 0.016923382878303528, -0.04322211444377899, -0.020467963069677353, -0.06152668595314026, -0.15959540009498596, -0.042700063437223434, -0.052684590220451355, 0.03866428881883621, 0.16081736981868744, -0.02651260793209076, -0.027393512427806854, -0.03759099170565605, -0.04128269478678703, 0.12377902120351791, 0.12992438673973083, 0.10562865436077118, 0.0028962900396436453, 0.04549611359834671, -0.16865462064743042, 0.03254999220371246, 0.02833574451506138, -0.17231610417366028, 0.04961828142404556, -0.01992664858698845, -0.08961349725723267, 0.007642653770744801, -0.16281193494796753, 0.006376020610332489, -0.026251409202814102, -0.04605131223797798, -0.10840743035078049, 0.050051961094141006, -0.06090832129120827, -0.0137301255017519, 0.17426879703998566, 0.078639455139637, 0.020023146644234657, 0.023282624781131744, 0.03874665126204491, -0.032589156180620193, 0.17838841676712036, -0.040741439908742905, 0.05235856771469116, -0.007811343297362328, -0.02469002828001976, 0.1017763614654541, 0.09655043482780457, 0.04838544875383377, -0.08152212202548981, -0.059150684624910355, 0.001234416151419282, 0.09656547009944916, 0.005384616553783417, 0.0183300469070673, 0.03216179460287094, -0.07541324943304062, 0.09280665963888168, -0.10066916048526764, -0.15090379118919373, -0.07151183485984802, 0.10085122287273407, -0.07613174617290497, 0.07707838714122772, 0.056087180972099304, 0.08737923204898834, 0.045971132814884186, 0.06879666447639465, -0.15467217564582825, -0.09780189394950867, -0.015255467966198921, 0.20302346348762512, 0.006069969851523638, -0.07660722732543945, -0.08131518214941025, -0.1041136160492897, -0.01026915106922388, 0.10488912463188171, 0.02375335432589054, -0.052726417779922485, -0.01472529023885727, -0.04436541348695755, -0.1306280791759491, 0.05875948816537857, -0.07690770924091339, -0.00487976148724556, 0.0107272919267416, -0.08178012818098068, -0.02953234687447548, -0.059136632829904556, -0.08280900120735168, -0.030154749751091003, -0.05931239202618599, -0.05131500959396362, -0.05156470462679863, -0.004875504411756992, 0.018467653542757034, 0.030532995238900185, 0.060062285512685776, 0.10271591693162918, 0.031339943408966064, 0.021427106112241745, 0.0806887149810791, -0.15666213631629944, 9.159637121967519e-33, 0.04251456260681152, 0.0615980327129364, -0.046266842633485794, -0.19692927598953247, -0.09462492167949677, 0.0021243076771497726, -0.005053891334682703, -0.0401889905333519, 0.0007929261773824692, 0.04212460666894913, -0.009664923883974552, 0.04655487462878227, 0.00688989507034421, 0.05512501299381256, 0.00092290248721838, -0.004503501579165459, 0.032983917742967606, 0.037562862038612366, -0.054314542561769485, 0.012111661955714226, -0.05242543667554855, 0.012971872463822365, -0.1224248856306076, -0.07506345212459564, -0.07300333678722382, -0.05861007422208786, -0.0498119480907917, 0.07476548850536346, -0.13913604617118835, -0.011683156713843346, -0.03286579251289368, 0.07432229071855545, 0.07276420295238495, -0.06391880661249161, 0.007206817157566547, -0.09774404764175415, -0.044708251953125, -0.008920203894376755, 0.10482918471097946, -0.03871142864227295, -0.012462669983506203, 0.18856710195541382, -0.033172063529491425, -0.049660272896289825, 0.13274206221103668, 0.035752907395362854, -0.13010674715042114, -0.07333366572856903, -0.11674416065216064, -0.12872973084449768, -0.03200637549161911, 0.06628437340259552, -0.1207292228937149, -0.0061310771852731705, -0.07956228405237198, 0.004400421865284443, -0.028682975098490715, -0.14507436752319336, 0.06609660387039185, 0.06833929568529129, -0.03134128823876381, 0.15864691138267517, -0.06684787571430206, -0.08426234126091003, -0.17921438813209534, 0.257770836353302, 0.005324811674654484, 0.13608288764953613, -0.11892235279083252, 0.12792164087295532, 0.034314192831516266, -0.04525572061538696, 0.05798841267824173, -0.05459747463464737, 0.038709238171577454, -0.01781431771814823, -0.020270850509405136, 0.1018783301115036, 0.11127259582281113, -0.05931483209133148, 0.05708198621869087, 0.00202192272990942, 0.12556247413158417, -0.057499147951602936, -0.048913344740867615, -0.10437294840812683, -0.08283567428588867, -0.025493131950497627, -0.1202457919716835, 0.05665832385420799, 0.1518850177526474, 0.017388436943292618, -0.15014517307281494, 0.18521186709403992, -0.015257995575666428, -9.883276587121504e-33, -0.11554562300443649, -0.01539824903011322, 0.0029764706268906593, 0.029599502682685852, -0.05097602307796478, 0.04243455082178116, 0.031007541343569756, -0.02751311846077442, 0.035595979541540146, -0.03308773413300514, -0.0715380311012268, -0.006567011121660471, -0.11467491090297699, 0.05743827670812607, 0.013658994808793068, -0.018858283758163452, 0.07746438682079315, -0.019278250634670258, 0.06369087100028992, -0.052916090935468674, -0.053155623376369476, 0.00555332750082016, -0.09636262059211731, 0.13803710043430328, 0.1074981763958931, 0.0817454531788826, 0.07081262022256851, 0.020796488970518112, -0.014319140464067459, -0.13198627531528473, -0.09058263152837753, 0.03167622908949852, -0.10903146862983704, 0.05169789865612984, -0.03248642757534981, 0.10633273422718048, -0.03428558260202408, -0.10258493572473526, -0.0542086660861969, -0.00912604108452797, 0.062125299125909805, -0.00343953724950552, 0.05861011520028114, -0.09079673141241074, 0.0389665886759758, 0.021958542987704277, 0.1433280110359192, 0.06822548061609268, 0.1023743599653244, 0.021625930443406105, 0.04710419476032257, 0.08155424147844315, 0.004424824845045805, 0.15211498737335205, -0.0574636235833168, -0.02470673993229866, -0.042249418795108795, 0.0670989453792572, 0.066623255610466, 0.0417105033993721, 0.08254282176494598, 0.16640090942382812, 0.03353670984506607, -0.045238107442855835, -0.0038412418216466904, 0.06674034893512726, -0.042180195450782776, -0.02224012091755867, 0.026459570974111557, -0.07455229759216309, -0.002086865482851863, -0.06468252092599869, 0.0743073970079422, -0.024691514670848846, -0.05831718444824219, 0.12233378738164902, -0.051869817078113556, -0.1401367485523224, -0.05868895351886749, 0.08146119117736816, 0.006754121743142605, 0.05590353161096573, -0.007585581392049789, 0.02586272731423378, -0.05869513005018234, 0.04785368591547012, -0.09679087996482849, 0.09279128164052963, -0.03917372226715088, 0.09304285049438477, -0.027104811742901802, -0.1818779855966568, -0.08939242362976074, -0.020248424261808395, 0.04915955290198326, -1.0006293393871601e-07, -0.09598005563020706, -0.05460476502776146, 0.09706756472587585, -0.02694808691740036, 0.0248927790671587, -0.04701279476284981, 0.05846874415874481, -0.08611313253641129, 0.08376789838075638, 0.06150432676076889, 0.13223330676555634, 0.0173923559486866, -0.2310156524181366, 0.08668840676546097, -0.14348644018173218, 0.021218840032815933, -0.10092450678348541, 0.008997384458780289, 0.06119295209646225, 0.008851513266563416, 0.05744647979736328, 0.01476631872355938, 0.010864492505788803, -0.08693994581699371, 0.14064921438694, -0.07444620877504349, -0.11089523136615753, 0.15107396245002747, -0.021830152720212936, 0.05728995054960251, 0.04514271020889282, -0.08731123805046082, 0.13900448381900787, 0.007783160079270601, 0.13622675836086273, 0.061531566083431244, 0.10561059415340424, 0.04962809383869171, 0.046153947710990906, 0.058638960123062134, -0.03455653786659241, -0.0021682213991880417, 0.003300237702205777, -0.02136629819869995, 0.0037664957344532013, -0.0490688756108284, -0.13816529512405396, 0.10744333267211914, 0.01608547940850258, -0.1924690306186676, 0.1350850760936737, -0.05107012391090393, 0.06771652400493622, 0.0752294659614563, 0.06809315085411072, 0.018598919734358788, -0.12174243479967117, -0.07615883648395538, -0.14163215458393097, -0.016117079183459282, 0.10147827118635178, -0.15391325950622559, -0.02760661579668522, 0.17993588745594025], "changes": {"1wk": -16.72862595210109, "1mo": -30.669146101661326}}, {"text": "EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference EyePoint Pharmaceuticals, Inc. Tue, Dec 17, 2024, 3:00 PM 2 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com . About EyePoint Pharmaceuticals EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E \u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU \u2122 (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E \u2122 . DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in\u00a0the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E \u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert \u00ae drug delivery technology has been safely administered to thousands of patient eyes across four\u00a0U.S.\u00a0FDA approved products.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Story Continues Investors: Christina Tartaglia Precision AQ Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-12-17T12:00:00+00:00", "sentiment": {"score": 0.3137495080009103, "confidence": 0.3215668499469757, "probabilities": {"positive": 0.3215668499469757, "negative": 0.007817341946065426, "neutral": 0.6706157922744751}}, "embedding": [-0.1125585287809372, -0.11766503751277924, 0.04647742584347725, -0.11377796530723572, 0.05638047307729721, -0.09974588453769684, -0.022907765582203865, 0.28171616792678833, 0.026633745059370995, 0.09997666627168655, -0.0657380148768425, 0.06492414325475693, 0.010485238395631313, 0.11682303249835968, -0.05762498080730438, 0.08623545616865158, -0.090673066675663, 0.1110738068819046, -0.024033766239881516, 0.010635518468916416, 0.19167791306972504, -0.0058446782641112804, 0.02117086946964264, 0.02170376293361187, -0.14714911580085754, 0.046802230179309845, -0.013890475034713745, 0.015783770009875298, -0.22393305599689484, -0.15227964520454407, 0.014338894747197628, 0.046316005289554596, -0.02284560352563858, -0.07554260641336441, -0.03634018823504448, 0.03667164593935013, -0.1270962506532669, -0.06977187097072601, -0.22961650788784027, -0.09917257726192474, -0.07184788584709167, -0.06993462890386581, -0.15206876397132874, 0.089485302567482, 0.20645847916603088, -0.21920466423034668, -0.07099639624357224, 0.1045125275850296, -0.09324674308300018, 0.1275823712348938, -0.14461877942085266, -0.06923417747020721, -0.04081665724515915, 0.06656471639871597, 0.004253989551216364, 0.09472154080867767, -0.27736085653305054, -0.009040392935276031, 0.12039466202259064, -0.02656451240181923, 0.026883631944656372, -0.05322515219449997, 0.028648534789681435, -0.007159853354096413, 0.008197633549571037, 0.0578344389796257, 0.12157964706420898, -0.07444985210895538, 0.03311964124441147, -0.03285222500562668, 7.88085162639618e-06, -0.07653868198394775, 0.02831212989985943, 0.11585883051156998, -0.09178976714611053, 0.13240519165992737, 0.11660395562648773, 0.05385460704565048, 0.07191553711891174, -0.0738321915268898, 0.18955156207084656, 0.10729706287384033, 0.1186281144618988, 0.002677168697118759, 0.097147636115551, 0.021336007863283157, -0.07979647815227509, 0.07561241090297699, 0.09892135858535767, -0.03282390534877777, 0.1164507046341896, 0.030023567378520966, -0.1277708113193512, 0.002015272155404091, 0.0009840354323387146, -0.059490591287612915, -0.11907821893692017, 0.008342329412698746, -0.05110602080821991, -0.02205963060259819, 0.030484959483146667, 0.044612862169742584, -0.06154365837574005, -0.08363710343837738, -0.013839228078722954, -0.04156972095370293, 0.15911820530891418, 0.021224061027169228, 0.06441974639892578, 0.0516490712761879, -0.0799282044172287, 0.04180699959397316, -0.018370192497968674, 0.026170257478952408, -0.048748791217803955, 0.14178171753883362, -0.0777716338634491, 0.011646302416920662, 0.34742867946624756, -0.05114796757698059, 0.08394759893417358, 0.0785989910364151, 0.03907458484172821, -0.10805211961269379, 0.1050567477941513, 0.03827385976910591, -0.08933255821466446, 8.918303723639888e-33, -0.02936815470457077, 0.063882976770401, -0.02875312976539135, 0.0537777915596962, -0.003774404525756836, -0.021532254293560982, 0.043069154024124146, 0.08566388487815857, -0.31326982378959656, -0.13211697340011597, -0.250413715839386, -0.08118855953216553, -0.00848257727921009, 0.23735705018043518, -0.07104266434907913, -0.1366291493177414, 0.04543718695640564, 0.14221470057964325, -0.038811735808849335, -0.0561373196542263, -0.06588412076234818, 0.1255244016647339, -0.07446271181106567, 0.028479864820837975, -0.04168328270316124, 0.06467428058385849, 0.00954859983175993, 0.14863988757133484, 0.14174465835094452, 0.0630553737282753, -0.1502721607685089, 0.07475695013999939, 0.04759558290243149, -0.1413111537694931, -0.012102503329515457, -0.053207360208034515, -0.02060507796704769, -0.13760703802108765, 0.09363716095685959, 0.0411306731402874, -0.01679632067680359, 0.1406552493572235, -0.0934651792049408, -0.08830119669437408, 0.07388252019882202, 0.010212443768978119, -0.09960445761680603, 0.1689203381538391, -0.05986517295241356, -0.039709143340587616, -0.00019489671103656292, -0.05513506755232811, -0.10215917229652405, -0.14212378859519958, -0.05069643259048462, 0.05062776058912277, -0.21415914595127106, -0.05455794185400009, 0.15625974535942078, 0.09439851343631744, -0.026707766577601433, 0.10930691659450531, -0.05926188826560974, 0.08848613500595093, -0.047637030482292175, -0.02409471571445465, -0.00999365746974945, -0.01753653772175312, -0.1572490632534027, 0.018091829493641853, 0.04738577455282211, 0.01083922665566206, 0.17532837390899658, -0.0012053963728249073, 0.14487388730049133, -0.05232948809862137, 0.09590555727481842, 0.2089882493019104, 0.10075455904006958, -0.011189136654138565, -0.03410538285970688, 0.02391989901661873, -0.09133758395910263, 0.0707949846982956, -0.015770558267831802, -0.06762948632240295, 0.012500898912549019, -0.034012939780950546, -0.1304306983947754, -0.06472235918045044, 0.2485542595386505, -0.10539838671684265, -0.01510537974536419, 0.034658852964639664, -0.008647095412015915, -7.86350178592034e-33, -0.03598027676343918, 0.007518300786614418, 0.1049647107720375, 0.06205587834119797, -0.051057055592536926, 0.15937526524066925, 0.1206168681383133, -0.16334031522274017, 0.24548748135566711, -0.21158218383789062, 0.056235093623399734, 0.009555656462907791, -0.01164139062166214, -0.13318488001823425, -0.06287311017513275, 0.13244491815567017, -0.05776970833539963, -0.10475118458271027, -0.19831421971321106, 0.045770637691020966, 0.06656559556722641, 0.061839986592531204, -0.021647825837135315, -0.01885487511754036, 0.06103254109621048, 0.06885559111833572, 0.14855585992336273, 0.004852600395679474, 0.0036822594702243805, 0.02087545394897461, -0.06449563801288605, 0.055987194180488586, -0.3257293105125427, 0.017321418970823288, -0.05059158056974411, 0.10279777646064758, -0.033931393176317215, -0.21394366025924683, -0.05968087166547775, -0.13506637513637543, 0.11077257990837097, -0.051614679396152496, -0.0265665166079998, -0.044350914657115936, 0.020615817978978157, 0.09885232895612717, 0.0988549068570137, 0.0430530309677124, 0.12137854099273682, -0.007873903028666973, -0.14203736186027527, 0.020718112587928772, -0.020869530737400055, 0.04115203395485878, -0.07366736233234406, 0.05539047718048096, 0.08107797801494598, -0.03563932329416275, -0.06754744052886963, 0.07341556996107101, 0.05902474373579025, -0.03762830048799515, 0.07021693140268326, -0.024981414899230003, 0.09561675041913986, 0.10723091661930084, 0.12396079301834106, 0.10784687101840973, 0.10538925975561142, -0.08383121341466904, 0.08228643238544464, -0.015468232333660126, 0.004193548113107681, -0.07175351679325104, 0.006640469655394554, 0.08733005821704865, -0.0050260936841368675, -0.11006484925746918, -0.2848561406135559, 0.052650824189186096, 0.12095215916633606, -0.06217753887176514, -0.07503873109817505, 0.09546950459480286, 0.03142619505524635, 0.06418544054031372, 0.13012747466564178, -0.0319761298596859, -0.015332624316215515, 0.05909819155931473, -0.1498824506998062, -0.11435931921005249, -0.19397205114364624, 0.23315922915935516, 0.09048255532979965, -9.966559844087897e-08, 0.06319259852170944, -0.04202786087989807, -0.026590900495648384, -0.14905044436454773, -0.025079991668462753, -0.10931418836116791, -0.013002417981624603, 0.16309750080108643, -0.05877125263214111, 0.05640988424420357, -6.69974833726883e-05, 0.12402164191007614, -0.07928641140460968, 0.0808643251657486, 0.03350836783647537, 0.08876080811023712, 0.05754077434539795, 0.06473176926374435, -0.07852848619222641, -0.058941666036844254, -0.12812025845050812, -0.01692723110318184, 0.05298726633191109, -0.041991498321294785, -0.020751144737005234, -0.06059765815734863, -0.006774525623768568, 0.104501873254776, 0.04625849425792694, -0.10756322741508484, 0.10155598819255829, 0.01220361702144146, 0.11103637516498566, 0.06012677773833275, -0.04805517941713333, -0.1503472924232483, 0.004572233185172081, 0.18769386410713196, 0.046216074377298355, 0.1677570939064026, -0.0927460640668869, 0.006236227694898844, 0.06167742609977722, 0.07140924036502838, -0.01528322696685791, -0.09032566845417023, -0.010153157636523247, 0.05087646096944809, -0.10949457436800003, -0.06927026808261871, -0.08908559381961823, 0.038641057908535004, -0.06793534755706787, -0.11696389317512512, -0.08004923164844513, 0.0732637494802475, -0.025871997699141502, -0.08267456293106079, 0.02061428129673004, -0.12076283246278763, 0.005001196637749672, -0.11445558071136475, 0.09062261879444122, 0.08066393435001373], "changes": {"1wk": -9.601002666007101, "1mo": -4.114717976403102}}, {"text": "EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU\u2122 for the Treatment of Wet Age-Related Macular Degeneration EyePoint Pharmaceuticals, Inc. Wed, Dec 4, 2024, 3:00 PM 11 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. \u2013 Topline data for Phase 3 pivotal program anticipated in 2026 \u2013 WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company\u2019s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E\u2122 for sustained intraocular delivery. \u201cDosing the first patient in our second global Phase 3 clinical trial, the LUCIA trial, marks another significant milestone demonstrating our continued focus on execution at EyePoint,\u201d said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. \u201cWe are encouraged by the robust physician and patient interest in DURAVYU with enrollment in our first pivotal trial, the LUGANO trial, exceeding our expectations. With two simultaneous Phase 3 clinical trials underway, the most robust clinical dataset of all long-acting treatments in development for wet AMD, and a strong balance sheet, we are well-positioned as the leader in sustained-release ocular drug delivery bringing impactful therapies to patients suffering from serious retinal diseases.\u201d \u201cWe are pleased to have dosed the first patient in the LUCIA trial so soon after dosing the first patient in the LUGANO trial. This underscores our commitment to develop innovative therapies with the potential to change the current treatment paradigm in wet AMD,\u201d said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint. \u201cThe Phase 3 pivotal program is the first and only sustained release wet AMD pivotal program evaluating re-dosing in both trials. Following a typical non-inferiority approval pathway, the LUGANO and LUCIA trials will provide data on the efficacy, durability, safety and dosing flexibility of treatment with DURAVYU and have the potential to provide the retina community valuable insights on how DURAVYU could be used in \u2018real-world\u2019 practice. With over 240 global sites already committed across both Phase 3 trials and exceptional patient and investigator enthusiasm, we are confident we can rapidly enroll patients in the Phase 3 pivotal trials.\u201d \u201cPatients with wet AMD typically require life-long treatment with frequent intravitreal injections to preserve their vision.\u00a0\u00a0This high treatment burden often results in under-treatment and irreversible vision loss,\u201d said Adam Gerstenblith, M.D., principal investigator in the LUCIA clinical trial and vitreoretinal surgeon at Mid Atlantic Retina Specialists. \u201cThe Phase 3 LUCIA trial is an important step forward in our pursuit of more durable treatments that are safe and effective. Moreover, the design of the LUCIA trial includes both treatment na\u00efve and previously treated wet AMD patients, as well as re-dosing of DURAVYU every six months, which aligns well with how we would approach potential treatment using DURAVYU in clinical practice. We are proud to be the site to treat a patient with DURAVYU in the LUCIA trial and we look forward to continuing to work with EyePoint to rapidly enroll patients in this critical Phase 3 program.\u201d Story Continues LUGANO and LUCIA are global, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including treatment na\u00efve and treatment experienced patients. Each trial is expected to enroll approximately 400 patients globally who will be randomly assigned to a 2.7mg dose of DURAVYU or an on-label aflibercept control. The LUGANO and LUCIA trials are the only sustained release wet AMD pivotal Phase 3 trials evaluating re-dosing in both trials. Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial. DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current standard practice with FDA approved anti-VEGF treatments. The primary endpoint of the Phase 3 pivotal trials is the average change in best corrected visual acuity (BCVA) at weeks 52 and 56 versus baseline. Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections and anatomical results as measured by optical coherence tomography (OCT). More information about the trial is available at clinicaltrials.gov (LUGANO identifier: NCT06668064; LUCIA identifier: NCT06683742). About Wet AMD Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss and irreversible blindness in people over the age of 50. Wet AMD is an advanced form of condition that develops when abnormal blood vessels grow into the macular retina, leaking blood or fluid, and leading to potentially severe vision loss. Wet AMD is a lifelong disease that requires continuous treatment so that patients may maintain visual function. Although multiple treatments are now available, challenges still exist as the current standard-of-care is dosed on average every two months in\u00a0the United States\u00a0under a treat-and-extend protocol, and these large molecule anti-VEGF treatments only target one pathology of the disease. This lifetime of frequent treatment represents a tremendous burden for patients, physicians, and the health care system, potentially leading to patient noncompliance and further vision loss. About DURAVYU \u2122 DURAVYU TM , f/k/a EYP-1901, is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. DURAVYU delivers vorolanib, a potent, selective and patent-protected tyrosine kinase inhibitor (TKI) as a solid bioerodible insert using EyePoint\u2019s proprietary sustained-release Durasert E \u2122 technology. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor inhibitor, inhibiting all VEGF receptors. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection and may have antifibrotic benefits as it also blocks PDGF. DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection in the physician's office. DURAVYU is immediately bioavailable with zero-order kinetics release for at least six months. Positive data from both the Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials of DURAVYU in wet AMD demonstrated clinically meaningful efficacy data with stable visual acuity and CST and a favorable safety profile. Further, data from DAVIO 2 demonstrated an impressive treatment burden reduction of approximately 88% at eight months, six months after treatment with DURAVYU, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection through up to eight months, six months after treatment with DURAVYU. The data from the DAVIO 2 clinical trial supported the advancement of the wet AMD program and the initiation of the global Phase 3 clinical trials, LUGANO and LUCIA. DURAVYU is also currently being studied in the Phase 2 VERONA trial for diabetic macular edema (DME). Full topline data is expected in the first quarter of 2025. About EyePoint Pharmaceuticals EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E \u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU \u2122 (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E \u2122 . DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in\u00a0the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E \u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert \u00ae drug delivery technology has been safely administered to thousands of patient eyes across four\u00a0U.S.\u00a0FDA approved products.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the pace of enrollment for the LUGANO trial and the LUCIA trial for wet AMD, and our beliefs and expectations regarding the anticipated announcement of full topline data from the VERONA trial in the first quarter of 2025; the belief that the interim results from the VERONA trial support DURAVYU\u2019s potential to advance to non-inferiority pivotal trials in DME; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as \u201cwill,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cintends,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cmay,\u201d other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint\u2019s actual results to be materially different than those expressed in or implied by EyePoint\u2019s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company\u2019s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company\u2019s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company\u2019s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company\u2019s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney\u2019s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company\u2019s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Precision AQ (formerly Stern IR) Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-12-04T12:00:00+00:00", "sentiment": {"score": 0.8328666901215911, "confidence": 0.8406478762626648, "probabilities": {"positive": 0.8406478762626648, "negative": 0.007781186141073704, "neutral": 0.15157100558280945}}, "embedding": [-0.04839269816875458, -0.10297505557537079, 0.04587293416261673, -0.0877809226512909, 0.0519658625125885, -0.21081113815307617, -0.03282807767391205, 0.18512041866779327, 0.09978983551263809, 0.13599024713039398, -0.012186502106487751, 0.04391687363386154, -0.03269204869866371, 0.11169616878032684, -0.033157408237457275, 0.09601688385009766, -0.0588826909661293, 0.027753233909606934, -0.013211779296398163, 0.10289596021175385, 0.17653919756412506, -0.07150804996490479, -0.022328320890665054, 0.09159593284130096, -0.13489791750907898, 0.06742902845144272, 0.008235775865614414, 0.0029816171154379845, -0.10534420609474182, -0.18101538717746735, 0.06957514584064484, 0.12081040441989899, -0.05788121372461319, -0.09104225039482117, -0.01814868114888668, 0.01611817255616188, -0.15391108393669128, -0.11657027900218964, -0.25608301162719727, -0.012873832136392593, -0.04235488176345825, -0.03833342343568802, -0.19028925895690918, 0.11385361105203629, 0.21890932321548462, -0.20798169076442719, -0.06831465661525726, 0.10478826612234116, 0.0033949152566492558, 0.1614498347043991, -0.11461369693279266, -0.14153149724006653, -0.03715463727712631, 0.0718657523393631, -0.045470431447029114, 0.06447525322437286, -0.20448872447013855, 0.0009154113940894604, 0.12772968411445618, -0.0064506554044783115, -0.010685281828045845, -0.060162290930747986, 0.02927422896027565, -0.00512899924069643, -0.015190951526165009, 0.027354702353477478, 0.07901991903781891, -0.08418162912130356, 0.007656662724912167, -0.03146190568804741, -0.024587757885456085, 0.03640611469745636, 0.11711045354604721, 0.08069291710853577, -0.07682867348194122, 0.08162273466587067, 0.06585706770420074, 0.01193814817816019, 0.04396114498376846, -0.07946953922510147, 0.1713097095489502, 0.0403791218996048, 0.08156272768974304, 0.014804062433540821, 0.09376773983240128, -0.0023740455508232117, -0.02591075375676155, 0.05382552742958069, 0.04595251381397247, -0.01693224161863327, 0.13026486337184906, 0.07536659389734268, -0.09524329006671906, 0.011915079317986965, 0.03378285840153694, -0.049761440604925156, -0.09293168038129807, 0.015569551847875118, -0.0661545991897583, 0.042652297765016556, 0.02210315130650997, -0.006409237161278725, -0.04206471890211105, -0.04006664827466011, 0.002832268364727497, -0.09136883169412613, 0.2255779206752777, -0.0794219896197319, 0.008097050711512566, 0.02107233926653862, -0.10448573529720306, 0.008562082424759865, 0.03474900498986244, 0.03946930170059204, -0.05916324257850647, 0.20396646857261658, -0.1129685789346695, 0.0381203219294548, 0.3456330895423889, -0.05613104999065399, 0.15054941177368164, 0.01645679958164692, 0.06801506131887436, -0.10901674628257751, 0.11435726284980774, 0.07203088700771332, 0.0476805604994297, 9.553884702921867e-33, 0.03475278243422508, -0.016403060406446457, -0.05851946398615837, 0.05479475110769272, -0.04650188609957695, -0.09900123625993729, 0.005585251841694117, 0.027372917160391808, -0.2935607433319092, -0.1644759476184845, -0.25457701086997986, -0.10386225581169128, -0.054372914135456085, 0.23574891686439514, -0.05588105320930481, -0.13456980884075165, 0.045642148703336716, 0.13234198093414307, -0.06959943473339081, 0.06806527823209763, 0.023473933339118958, 0.07435105741024017, -0.10478441417217255, 0.014467726461589336, -0.09675757586956024, 0.1400151550769806, -0.059664130210876465, 0.06878259778022766, 0.11140915006399155, 0.0948338657617569, -0.15609049797058105, 0.06953246891498566, 0.0031861832831054926, -0.052393682301044464, -0.06626458466053009, -0.0023236311972141266, -0.04628317803144455, -0.11203835904598236, 0.050226032733917236, 0.046827949583530426, -0.07955043017864227, 0.12328850477933884, -0.06082119420170784, -0.08106918632984161, 0.02088114432990551, -0.06285986304283142, -0.0892748087644577, 0.11130519211292267, -0.009099920280277729, -0.11603978276252747, 0.004397938027977943, -0.0559081956744194, -0.08827721327543259, -0.12198805809020996, -0.016025973483920097, 0.09064220637083054, -0.1976185142993927, -0.017350707203149796, 0.10568009316921234, 0.10336020588874817, 0.02075050212442875, 0.05359925329685211, -0.03983284533023834, 0.1636146605014801, -0.05381373316049576, -0.011801514774560928, 0.04184850677847862, -0.011412195861339569, -0.0859052985906601, -0.09800811111927032, -0.052682146430015564, -0.1001666858792305, 0.20018929243087769, 0.020403197035193443, 0.060925669968128204, -0.012773226946592331, 0.1922321617603302, 0.1632232666015625, 0.014749409630894661, -0.015698079019784927, -0.0376904122531414, -0.0038831625133752823, -0.12011082470417023, 0.09720924496650696, -0.0357368029654026, 0.007192348130047321, 0.05161379650235176, -0.04062969610095024, -0.18186815083026886, -0.008741986937820911, 0.1904933750629425, -0.07729891687631607, -0.001827627420425415, -0.09232904762029648, 0.07241471111774445, -1.0318787693209561e-32, 0.02390679530799389, 0.00406080624088645, 0.05766989290714264, 0.027170270681381226, -0.05803336948156357, 0.21996119618415833, 0.10223782062530518, -0.14980442821979523, 0.17048165202140808, -0.2060590237379074, -0.0221469234675169, 0.003014722838997841, -0.07634559273719788, -0.13751550018787384, -0.07793962210416794, 0.0844898670911789, -0.04528156667947769, -0.04605740308761597, -0.11681961268186569, 0.02218484692275524, 0.10227403044700623, 0.07380160689353943, 0.027782727032899857, -0.04086093604564667, 0.09558413922786713, 0.04830750450491905, 0.15654674172401428, 0.00046386197209358215, -0.06233423203229904, 0.003625853918492794, -0.16519132256507874, 0.09614811092615128, -0.2310183346271515, 0.0247983206063509, -0.06047172099351883, 0.14881286025047302, 0.018504194915294647, -0.1899668276309967, -0.10760415345430374, -0.08534110337495804, 0.03766970708966255, -0.08218517154455185, -0.04393627867102623, -0.061148643493652344, 0.02605953812599182, 0.13727037608623505, 0.06320797652006149, 0.025065170601010323, 0.13607147336006165, -0.053282253444194794, -0.14590610563755035, 0.041711464524269104, -0.03623012453317642, 0.017386682331562042, -0.02682340145111084, -0.0694441944360733, 0.026559976860880852, -0.06489308923482895, -0.06981885433197021, 0.05986027047038078, 0.01770286075770855, -0.030834924429655075, 0.005748342722654343, -0.05866962671279907, 0.07749764621257782, 0.15180689096450806, 0.08840356767177582, 0.08005490899085999, 0.09871115535497665, -0.0406089723110199, -0.0304130706936121, -0.0397363007068634, -0.1168343648314476, -0.06440920382738113, 0.06948952376842499, 0.09025886654853821, -0.07924970984458923, -0.0931088775396347, -0.2537164092063904, -0.05330006033182144, 0.06291990727186203, -0.032336361706256866, -0.07416841387748718, 0.10772611200809479, 0.013283975422382355, 0.05707741528749466, 0.1411057710647583, -0.08963111788034439, 0.010648648254573345, 0.0574069619178772, -0.13098937273025513, -0.08882039785385132, -0.20227274298667908, 0.19619208574295044, 0.0190433282405138, -1.0054648669211019e-07, 0.07632599771022797, 0.00408924138173461, 0.05998258292675018, -0.07243842631578445, 0.04528314620256424, -0.1392868459224701, -0.06985725462436676, 0.17813457548618317, -0.08821913599967957, 0.0816614106297493, -0.013148248195648193, 0.11296047270298004, 0.04346519708633423, -0.010031983256340027, 0.05908966809511185, 0.12394009530544281, 0.07171794772148132, 0.07268494367599487, -0.10810016840696335, -0.0561826191842556, -0.05568193271756172, -0.008014040067791939, 0.08427342772483826, -0.09205428510904312, 0.04952630773186684, -0.01536380872130394, -0.012396630831062794, 0.1119287759065628, 0.05647272244095802, -0.07274116575717926, 0.11810390651226044, 0.002500709146261215, 0.060501232743263245, 0.033969148993492126, -0.03644648939371109, -0.08865396678447723, -0.030028844252228737, 0.19654026627540588, 0.05855415016412735, 0.06432601809501648, -0.12760190665721893, 0.07277411222457886, 0.02535836584866047, 0.05159395933151245, -0.04099171981215477, -0.07793676853179932, -0.05394235998392105, -0.00625293143093586, -0.0688953697681427, -0.0815344825387001, -0.08931554108858109, 0.055010776966810226, -0.04440451040863991, 0.01972639560699463, -0.06107093766331673, 0.12444384396076202, 0.022721771150827408, -0.04911847785115242, -0.019091937690973282, -0.1120503842830658, 0.055471643805503845, -0.10301128029823303, 0.039606478065252304, 0.013631214387714863], "changes": {"1wk": -0.3533537547697758, "1mo": -5.41813958242768}}, {"text": "EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags editorial-team@simplywallst.com (Simply Wall St) Sat, Nov 9, 2024, 4:04 PM 1 min read In This Article: EYPT -6.27% EyePoint Pharmaceuticals ( NASDAQ:EYPT ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.5m (down 31% from 3Q 2023). Net loss: US$29.4m (loss widened by 133% from 3Q 2023). US$0.54 loss per share (further deteriorated from US$0.33 loss in 3Q 2023). NasdaqGM:EYPT Earnings and Revenue Growth November 9th 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period EyePoint Pharmaceuticals Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 2.8%. Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 3.6% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 4 warning signs for EyePoint Pharmaceuticals (2 are concerning!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-11-09T13:04:42+00:00", "sentiment": {"score": -0.8625027416273952, "confidence": 0.8768529891967773, "probabilities": {"positive": 0.01435024756938219, "negative": 0.8768529891967773, "neutral": 0.10879676043987274}}, "embedding": [-0.0020879085641354322, -0.05877167731523514, -0.08391284197568893, 0.030025506392121315, 0.0499483086168766, 0.04618341848254204, -0.005031629931181669, 0.1965731978416443, 0.08839374780654907, 0.02263648994266987, -0.06032079830765724, 0.1284743845462799, 0.02605849876999855, -0.005464805755764246, -0.051323406398296356, -0.023501815274357796, 0.009502863511443138, -0.09931819885969162, -0.04365143924951553, 0.08846398442983627, -0.035420116037130356, -0.06818843632936478, -0.005890456959605217, -0.01335484441369772, 0.007763606496155262, 0.02916400507092476, -0.12268508225679398, -0.008826165460050106, -0.1901627779006958, -0.1334819495677948, -0.060252994298934937, 0.054122161120176315, 0.10371521860361099, -0.07241293787956238, -0.020657194778323174, 0.04476265609264374, -0.06224860996007919, 0.08901375532150269, 0.08658035099506378, -0.036146923899650574, 0.001516793854534626, -0.05182449147105217, -0.10651004314422607, 0.009073305875062943, 0.043643321841955185, -0.17858631908893585, -0.05844971910119057, 0.057360630482435226, -0.016747746616601944, 0.06513897329568863, -0.1627332866191864, -0.015595334582030773, 0.0071104709059000015, 0.028618264943361282, -0.00887354090809822, -0.007155264262109995, -0.10902857780456543, -0.02229936420917511, 0.04911933094263077, -0.06712163984775543, 0.013815226964652538, 0.0504346564412117, 0.007470917422324419, 0.024704692885279655, 0.12061841785907745, 0.023149922490119934, 0.06477604061365128, 0.14337538182735443, -0.05214475840330124, -0.0011326686944812536, 0.008489069528877735, -0.030609292909502983, -0.10871808975934982, 0.045196082442998886, -0.04483332112431526, 0.17118586599826813, 0.1701572686433792, 0.08506551384925842, 0.07641088962554932, -0.11239298433065414, 0.09454050660133362, 0.05075116828083992, -0.12112003564834595, -0.06869742274284363, -0.08636095374822617, -0.06423507630825043, 0.10148422420024872, 0.06492454558610916, 0.1042807400226593, 0.007572959177196026, 0.15423619747161865, -0.02101908251643181, -0.06092790141701698, -0.03367583453655243, 0.13666124641895294, -0.041875652968883514, -0.16344769299030304, -0.13520941138267517, -0.07638027518987656, 0.05779309943318367, 0.1764354556798935, 0.05522677302360535, -0.09929530322551727, -0.11383482813835144, -0.060499195009469986, -0.06501246988773346, 0.08047409355640411, 0.035246822983026505, -0.02266668900847435, 0.09477225691080093, -0.0922633484005928, 0.0978531762957573, -0.1440872997045517, -0.11311890184879303, -0.002599218860268593, 0.031152358278632164, -0.08083568513393402, -0.09701176732778549, 0.22623920440673828, 0.01973165012896061, 0.08332419395446777, 0.17278878390789032, 0.0042906575836241245, -0.036254364997148514, 0.06751377135515213, -0.010965806432068348, -0.09503050893545151, 1.154789928010873e-32, 0.004204216878861189, 0.09454188495874405, 0.0060686892829835415, -0.14601503312587738, -0.02382795512676239, 0.10029995441436768, 0.051456570625305176, 0.0366349071264267, -0.10039275884628296, -0.057897359132766724, -0.2110072672367096, 0.08891796320676804, 0.050822194665670395, -0.06804683059453964, -0.008182461373507977, -0.07551500201225281, 0.0774640142917633, 0.06696950644254684, 0.013749677687883377, -0.0320059172809124, -0.06628917902708054, -0.06208834797143936, -0.04734176769852638, 0.0885414332151413, 0.068696990609169, -0.0028734812512993813, -0.03733058646321297, 0.005303995683789253, -0.07239842414855957, 0.04465614631772041, -0.060886502265930176, 0.07074955105781555, -0.03023957647383213, -0.04843432828783989, -0.021753180772066116, -0.06578309088945389, -0.17070765793323517, -0.013268180191516876, 0.13093359768390656, 0.006062610074877739, -0.10479209572076797, 0.14228563010692596, -0.024965008720755577, -0.05850059539079666, -0.0037014319095760584, 0.10159420222043991, -0.03530042618513107, 0.025509079918265343, -0.019367944449186325, -0.09098319709300995, -0.042417917400598526, 0.03438975661993027, -0.1426282525062561, -0.03366152569651604, -0.08756369352340698, 0.07152162492275238, -0.0046375105157494545, -0.14210745692253113, 0.09660734236240387, 0.0539112463593483, -0.01910458132624626, 0.2502131164073944, 0.019275618717074394, -0.10720939189195633, -0.24449706077575684, 0.10543736070394516, -0.11107458919286728, 0.08887583762407303, -0.051784008741378784, 0.080343097448349, -0.05605720356106758, -0.08686252683401108, 0.24564847350120544, -0.03125455603003502, 0.11105085164308548, 0.011178923770785332, -0.012491123750805855, 0.04252485930919647, 0.06552857160568237, 0.02829752117395401, 0.012429329566657543, 0.01747269183397293, 0.08202935010194778, -0.0493704192340374, -0.08172278851270676, -0.0258883535861969, 0.14278514683246613, -0.006796183530241251, -0.08005977421998978, 0.06618984788656235, -0.018076114356517792, 0.000553139194380492, -0.10394391417503357, 0.18390285968780518, -0.031149085611104965, -1.2104467937232251e-32, -0.03387841209769249, 0.017389923334121704, 0.0660209059715271, -0.07504444569349289, -0.11081331223249435, 0.010666310787200928, 0.08855967968702316, 0.07802601158618927, 0.03125113621354103, -0.06788117438554764, 0.02431090921163559, 0.024749623611569405, -0.09766755998134613, 0.03788934648036957, -0.020440304651856422, 0.028294702991843224, 0.09720776975154877, -0.11926683783531189, -0.024176539853215218, -0.0027357488870620728, 0.04106869176030159, 0.15144777297973633, -0.22006767988204956, 0.12381777912378311, 0.007281164638698101, 0.10851138085126877, 0.16544872522354126, 0.049065954983234406, -0.035496894270181656, -0.03264031186699867, -0.07164929807186127, -0.003626996884122491, -0.22113530337810516, 0.1359582394361496, -0.03756926953792572, 0.03632804751396179, 0.08699189126491547, -0.18802903592586517, -0.06486468762159348, -0.1255216747522354, 0.197975292801857, 0.1031375452876091, 0.046467505395412445, 0.04413685202598572, 0.029733048751950264, 0.029382100328803062, 0.1035623848438263, 0.027266988530755043, 0.0752163752913475, 0.1077885702252388, -0.009718633256852627, 0.0010963381500914693, -0.054144296795129776, 0.118157759308815, -0.1386333554983139, 0.018228555098176003, 0.01403458509594202, -0.041026100516319275, -0.09483164548873901, -0.0035230806097388268, 0.020726341754198074, 0.11820180714130402, -0.050766173750162125, -0.09290236234664917, 0.07519783079624176, -0.06582177430391312, 0.09632358700037003, -0.07275648415088654, 0.12734265625476837, -0.053579606115818024, 0.05367037281394005, -0.020362794399261475, 0.06677332520484924, -0.14849209785461426, 0.04818359389901161, 0.283124715089798, -0.03337519243359566, -0.1143222451210022, -0.1253465712070465, 0.0921182855963707, 0.09580536186695099, 0.04100562632083893, 0.036868393421173096, 0.04199626296758652, -0.02543693408370018, 0.07513624429702759, 0.03557991236448288, -0.02516010031104088, -0.0265498124063015, -0.023280104622244835, -0.16618244349956512, -0.15457095205783844, -0.10633683949708939, 0.03675566613674164, 0.10492772608995438, -9.994139560376425e-08, 0.019178789108991623, -0.09623531252145767, 0.11400267481803894, 0.029467463493347168, 0.05953767150640488, -0.10076181590557098, 0.05659837648272514, 0.00843026489019394, 0.04263586178421974, 0.11856171488761902, 0.052450381219387054, 0.010962486267089844, -0.23534783720970154, 0.00367028103210032, -0.09012044221162796, -0.02340778522193432, -0.1275109499692917, 0.03189191594719887, -0.06856802105903625, -0.13943016529083252, -0.03876620531082153, 0.06892184168100357, -0.05378493666648865, -0.06775831431150436, 0.13407550752162933, -0.11655856668949127, -0.008808497339487076, 0.04272789508104324, -0.0038112231995910406, -0.023082496598362923, 0.0483793281018734, -0.06610686331987381, 0.04129451885819435, -0.06420718133449554, 0.004486601799726486, -0.11667460203170776, 0.1943671703338623, 0.03321332484483719, 0.052817780524492264, 0.15341471135616302, -0.01911219395697117, -0.03624534234404564, 0.0667884424328804, 0.0029041178058832884, -0.05439264327287674, -0.10680446028709412, -0.11050700396299362, 0.007564496248960495, 0.0698133334517479, -0.1945287585258484, 0.1305493712425232, -0.09111302345991135, 0.024756990373134613, 0.05599876865744591, 0.0898742526769638, -0.031203895807266235, -0.10457613319158554, -0.0829881876707077, -0.09458615630865097, 0.0001868425460997969, 0.03500085324048996, -0.25287672877311707, 0.007638114504516125, 0.16780801117420197], "changes": {"1wk": -23.583332697550453, "1mo": -27.416666348775227}}, {"text": "EyePoint price target lowered to $33 from $38 at Baird TipRanks Tue, Nov 12, 2024, 2:45 PM In This Article: EYPT -6.27% https://www.tipranks.com/news/the-fly/gsk-announces-ema-accepted-for-review-the-maa-for-depemokimab Baird lowered the firm\u2019s price target on EyePoint ( EYPT ) to $33 from $38 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results and recapped recent progress, including recently reported, unexpectedly positive, interim data in the Phase 2 VERONA study in DME, and the dosing of the first patient in the pivotal LUGANO study in wet AMD. Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on EYPT: EyePoint Pharmaceuticals Advances in Retinal Therapeutics EyePoint reports Q3 EPS (54c), consensus (55c) EyePoint expect cash to fund operations into 2027 Biotech Alert: Searches spiking for these stocks today EyePoint 12.73M share Secondary priced at $11.00 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-11-12T11:45:45+00:00", "sentiment": {"score": -0.3147376999258995, "confidence": 0.3983619809150696, "probabilities": {"positive": 0.08362428098917007, "negative": 0.3983619809150696, "neutral": 0.5180137157440186}}, "embedding": [-0.12091751396656036, -0.11908000707626343, -0.026436608284711838, 0.054661933332681656, 0.054600123316049576, -0.04353329539299011, 0.09651248157024384, 0.2690563201904297, 0.12572205066680908, 0.1482258141040802, 0.035362809896469116, 0.049556877464056015, -0.018978675827383995, 0.030709993094205856, -0.05962728336453438, 0.019183514639735222, 0.13532760739326477, -0.07308261841535568, -0.012203903868794441, 0.04181603714823723, 0.02134973183274269, -0.11496009677648544, 0.07368607819080353, 0.029911261051893234, 0.07704519480466843, 0.061266183853149414, -0.08282732963562012, -0.08267112821340561, -0.15603089332580566, -0.13795779645442963, -0.1104423925280571, 0.008126160129904747, -0.10200043022632599, -0.07127557694911957, -0.026249218732118607, -0.07019206136465073, -0.04562746733427048, -0.05684427544474602, -0.015116658993065357, 0.022086376324295998, -0.002228828612715006, 0.022053349763154984, -0.2783181369304657, -0.005998147651553154, 0.10431556403636932, -0.17442169785499573, 0.008206686936318874, 0.08430984616279602, -0.04260386526584625, 0.000363149301847443, -0.16179922223091125, -0.16133590042591095, 0.012834365479648113, -0.005235380958765745, -0.023696275427937508, -0.02770478092133999, -0.19881600141525269, -0.011253654956817627, 0.14192818105220795, -0.008808176964521408, 0.02624514326453209, -0.03986404091119766, 0.05371969938278198, -0.03843674063682556, 0.11481895297765732, -0.06636388599872589, 0.037846654653549194, -0.12914404273033142, 0.1151689738035202, -0.04818064719438553, 0.018069259822368622, 0.014766091480851173, 0.1107167974114418, -0.044966571033000946, -0.07060093432664871, 0.14069630205631256, 0.17611008882522583, 0.02915412373840809, 0.08410817384719849, -0.04436197504401207, 0.11015604436397552, -0.13528692722320557, 0.04765011742711067, -0.015602386556565762, 0.13229058682918549, -0.11568574607372284, 0.024181237444281578, 0.11578228324651718, 0.12580810487270355, 0.07651524245738983, 0.1125890389084816, -0.058934763073921204, -0.17003005743026733, 0.005422509275376797, 0.05383027344942093, 0.0313430055975914, -0.2220313996076584, 0.013162466697394848, -0.07854961603879929, -0.050720181316137314, 0.10044404864311218, 0.09340418875217438, -0.016185862943530083, -0.04130585119128227, -0.04634735360741615, -0.08659414947032928, 0.18168143928050995, -0.0389266237616539, 0.0505724661052227, -0.01189133245497942, -0.13876184821128845, 0.0600406713783741, -0.06622777134180069, -0.05010179802775383, -0.113926962018013, 0.12608759105205536, -0.1094781830906868, -0.08651766926050186, 0.3070542514324188, -0.055796366184949875, 0.091086246073246, 0.0073899258859455585, 0.03608941659331322, -0.08831625431776047, 0.052080187946558, 0.036555297672748566, -0.22624079883098602, 9.088504285379416e-33, 0.06799556314945221, 0.10217968374490738, -0.07900755107402802, -0.15915969014167786, -0.11586757749319077, 0.05781976133584976, 0.02505486086010933, 0.050098538398742676, -0.1670021116733551, -0.08465524762868881, -0.1829967051744461, -0.039758164435625076, -0.00703123863786459, 0.16373024880886078, -0.054913219064474106, -0.13789190351963043, 0.043632205575704575, 0.07546532154083252, 0.015428265556693077, -0.016259606927633286, -0.09021846950054169, -0.056856732815504074, -0.12447920441627502, -0.06858844310045242, -0.000997150782495737, 0.11669105291366577, -0.08612105250358582, 0.01665318012237549, 0.03204578906297684, 0.13537433743476868, -0.09154848754405975, 0.04977911338210106, 0.014509052969515324, -0.03048592247068882, -0.017163489013910294, -0.0645579919219017, -0.09483053535223007, -0.07396367937326431, 0.10092303156852722, -0.013260560110211372, 0.032935742288827896, 0.2747983932495117, -0.0016019279137253761, -0.09701510518789291, -0.018817193806171417, 0.11627928912639618, -0.09737619757652283, 0.037485502660274506, 0.030395323410630226, -0.10346096009016037, -0.02661675028502941, 0.04972170293331146, -0.08933554589748383, -0.034840214997529984, -0.01854107715189457, 0.05329131335020065, -0.10213598608970642, -0.11078401654958725, 0.05950303003191948, 0.04398461803793907, -0.054634448140859604, 0.13465216755867004, -0.008368690498173237, 0.01148301362991333, -0.11842932552099228, 0.11391741037368774, -0.08181428909301758, 0.028300443664193153, -0.20871581137180328, 0.2365482747554779, 0.035628754645586014, -0.03137554973363876, 0.21355710923671722, -0.06508061289787292, 0.12909165024757385, -0.09513513743877411, 0.06078025698661804, 0.06596557796001434, 0.16333821415901184, 0.04066505655646324, 0.06015874817967415, -0.07910188287496567, 0.017106380313634872, 0.007709129713475704, -0.01227658987045288, -0.07542498409748077, 0.0019032866694033146, -0.03051816299557686, -0.12987205386161804, 0.034147489815950394, 0.1427154690027237, -0.021345369517803192, -0.11695548892021179, 0.052801426500082016, -0.011787911877036095, -8.684433979756009e-33, -0.039191361516714096, 0.12868425250053406, 0.028493262827396393, 0.0415920652449131, -0.18150028586387634, 0.07148005068302155, 0.1176394522190094, 0.01339353621006012, 0.21170969307422638, 0.10168998688459396, 0.0319061353802681, 0.0747307762503624, -0.06236090883612633, 0.0442260280251503, -0.03257755562663078, 0.050313279032707214, -0.06854809820652008, -0.09471740573644638, 0.14043326675891876, -0.1615525484085083, 0.055743783712387085, 0.018170908093452454, -0.023218756541609764, 0.13530968129634857, 0.08049654215574265, 0.09830203652381897, 0.13087302446365356, -0.04403034225106239, -0.12071233242750168, -0.09741177409887314, -0.12310069799423218, 0.03984874486923218, -0.06848620623350143, 0.14639657735824585, -0.13503529131412506, 0.09761746227741241, 0.07145608216524124, -0.19557419419288635, -0.028374843299388885, -0.05327725037932396, 0.1707656979560852, 0.01998891495168209, 0.10560590773820877, -0.023988714441657066, 0.06516622751951218, 0.043899137526750565, 0.07376646995544434, 0.141672745347023, 0.11659826338291168, 0.06303701549768448, -0.04064501076936722, 0.004339240491390228, -0.017574282363057137, 0.09066435694694519, -0.1712973564863205, -0.049262817949056625, 0.011934417299926281, 0.03405317664146423, -0.12943226099014282, 0.017243919894099236, 0.12104271352291107, 0.07540280371904373, -0.0958050861954689, 0.04572561755776405, -0.022008882835507393, 0.05180870369076729, 0.10659018903970718, 0.055766064673662186, 0.12918055057525635, -0.09887871891260147, 0.10721214860677719, -0.17564167082309723, 0.09144651144742966, -0.13566704094409943, 0.03745540976524353, 0.16820181906223297, -0.030166063457727432, -0.12520968914031982, -0.009005364961922169, -0.0550253726541996, 0.14075854420661926, -0.03508337214589119, 0.0380098856985569, 0.06553070992231369, 0.0046366676688194275, 0.11031263321638107, 0.016817202791571617, 0.0699436217546463, -0.1588369458913803, 0.08902036398649216, -0.20779584348201752, -0.14405596256256104, -0.05795387551188469, 0.17882633209228516, 0.12495061755180359, -9.973740588975488e-08, -0.03860832378268242, -0.05662496015429497, 0.05232754349708557, 0.039083611220121384, 0.08842696994543076, -0.09475245326757431, 0.005275346338748932, 0.23248830437660217, 0.021838998422026634, 0.14805029332637787, 0.004129620268940926, 0.012671388685703278, -0.032781753689050674, 0.08899152278900146, -0.006321069318801165, -0.04827176406979561, -0.014015975408256054, -3.000518336193636e-05, -0.06009555608034134, -0.09449774771928787, -0.02754736691713333, 0.13009247183799744, 0.1008075550198555, -0.05922447144985199, -0.05733893811702728, 0.04300094395875931, -0.04234014078974724, 0.13727280497550964, 0.03256019577383995, -0.015809055417776108, 0.020675605162978172, -0.01740472950041294, 0.12231768667697906, -0.004621685482561588, -0.13274827599525452, -0.15797428786754608, -0.0425419919192791, 0.09758599102497101, 0.03497832268476486, 0.1666473150253296, -0.13758909702301025, -0.07795614004135132, 0.027202662080526352, 0.05441346392035484, -0.04676242917776108, -0.03709355369210243, -0.1635158210992813, -0.05464349314570427, -0.013096613809466362, -0.11930818110704422, 0.058987006545066833, 0.003944230265915394, -0.04009575396776199, -0.005283281672745943, -0.09748237580060959, -0.030110884457826614, -0.12441686540842056, -0.018753519281744957, -0.12613801658153534, -0.09883017838001251, 0.1293627768754959, -0.3311043083667755, -0.10530733317136765, 0.14292758703231812], "changes": {"1wk": -22.77227552793515, "1mo": -25.74257196271245}}, {"text": "EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments EyePoint Pharmaceuticals, Inc. Thu, Nov 7, 2024, 3:00 PM 12 min read In this article: EYPT -6.27% EyePoint Pharmaceuticals, Inc. \u2013 Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile; BCVA and CST improvement of +8.9 letters and -68 microns, respectively, at 16-weeks \u2013 \u2013 Dosed first patient in Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU\u2122 in wet AMD; second LUCIA pivotal trial first patient dosing expected by end of 2024 \u2013 \u2013 $161.0 million oversubscribed equity financing extends cash runway into 2027 - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended\u00a0September 30, 2024,\u00a0and highlighted recent corporate developments. \u201cWe made tremendous progress across our pipeline in recent months, including dosing the first patient in our first global pivotal trial of DURAVYU\u2122 in wet AMD and reading out interim 16-week data for our Phase 2 VERONA trial in DME,\u201d said Jay Duker, M.D., President and Chief Executive Officer of EyePoint. \u201cDriven by positive clinical data in two indications, along with growing patient and investigator enthusiasm, we remain confident that DURAVYU\u2019s differentiated profile underscores its potential to be the first sustained-release maintenance therapy in two significant indications, positioning EyePoint as the leader in sustained ocular drug delivery. This is an exciting time for EyePoint, and we anticipate dosing the first patient in the second Phase 3 LUCIA trial by the end of 2024. With a strong balance sheet and compelling clinical data, we are well-positioned to continue executing across our pipeline, working to bring our potentially paradigm-shifting treatment to patients as fast as possible.\u201d R&D Highlights and Updates Announced positive interim 16-week data for the ongoing open label Phase 2 VERONA clinical trial of DURAVYU for diabetic macular edema (DME) in October. DURAVYU 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) with a gain of +8.9 letters compared to baseline versus +3.2 letters for aflibercept control. DURAVYU 2.7mg also demonstrated concomitant structural improvement with CST (central subfield thickness) improvement of 68.1 microns versus 30.5 microns for aflibercept control. Notably, both DURAVYU doses showed an immediate benefit over aflibercept control in both BCVA and CST demonstrating the differentiated drug release profile of DURAVYU with immediate bioavailability. Additionally, a favorable safety and tolerability profile continued for both DURAVYU arms. The Company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. Announced first patient dosed in the Phase 3 LUGANO clinical trial of DURAVYU TM in wet age-related macular degeneration (wet AMD). The second Phase 3 LUCIA pivotal trial initiation is expected to have first patient dosing by end of 2024. The LUGANO and LUCIA clinical trials are designed for potential global regulatory and commercial success with every six-month re-dosing in both trials. With over 160 trial sites committed and robust DAVIO 2 data, the company anticipates rapid enrollment of both trials with topline data anticipated in 2026. Presented DAVIO 2 twelve-month data at the American Academy of Ophthalmology (AAO) 2024 Subspecialty Day in October, at the 24 th EURetina Congress in September and the Retina Society 57 th Annual Meeting in September. Presented a comparison of tyrosine kinase inhibitors being developed for intravitreal delivery at the Retina Society 57 th Annual Meeting in September, demonstrating the differentiation of DURAVYU with immediate bioavailability and controlled release via zero-order kinetics for at least six months. Presented on sustained-release vorolanib highlighting selective pan-VEGF receptor inhibition and anti-angiogenic effects in VEGF-mediated ocular diseases at the American Retina Forum (ARF) 2024 National Meeting in August demonstrating the durable efficacy, reliable safety and reduced injection burden of treatment with DURAVYU. Story continues Recent Corporate Highlights Completed an underwritten public offering with gross proceeds of $161.0 million in October. The Company sold 14,636,363 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock. The shares of common stock were sold at a public offering price of $11.00 per share. Announced the grand opening of EyePoint\u2019s Northbridge, MA manufacturing facility in October. The 40,000 square foot Good Manufacturing Process (cGMP) compliant commercial manufacturing facility was built to meet U.S. FDA and European Medicines Agency (EMA) and will support global manufacturing across the Company\u2019s portfolio, including lead pipeline asset, DURAVYU TM upon potential regulatory approval. Announced the appointment of esteemed industry leader Fred Hassan to the Company\u2019s Board of Directors in September. Review of Results for the Third Quarter Ended September 30, 2024 For the third quarter ended September 30, 2024, total net revenue was $10.5 million compared to $15.2 million for the quarter ended September 30, 2023. Net product revenue for the third quarter was $0.7 million, compared to net product revenues for the third quarter ended September 30, 2023, of $0.8 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2024, totaled $9.9 million compared to $14.4 million in the corresponding period in 2023. This decrease was primarily driven by lower recognition of deferred revenue related to the out-license of YUTIQ \u00ae product rights. Operating expenses for the third quarter ended September 30, 2024, totaled $43.3 million versus $29.6 million in the prior year period. This increase was primarily driven by (i) $5.4 million in costs related to the DURAVYU\u2122 Phase 3 clinical trials for wet AMD, (ii) $3.8 million higher personnel expense for clinical and product development, including $2.1 million of non-cash stock compensation, (iii) $3 million in other R&D related expenses. Non-operating income, net, totaled $3.4 million and net loss was $29.4 million, or ($0.54) per share, compared to a net loss of $12.6 million, or ($0.33) per share, for the prior year period. Cash and investments at September 30, 2024 totaled $253.8 million compared to $331.1 million at December 31, 2023. Financial Outlook We expect the cash, cash equivalents and investments on September 30, 2024, along with the net proceeds from the October $161.0 million equity financing will enable us to fund operations into 2027. About EyePoint Pharmaceuticals EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E \u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU \u2122 (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E \u2122 . DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in\u00a0the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E \u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert \u00ae drug delivery technology has been safely administered to thousands of patient eyes across four\u00a0U.S.\u00a0FDA approved products.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of\u00a0China,\u00a0Macao,\u00a0Hong Kong\u00a0and\u00a0Taiwan. DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the announcement of full topline data from the VERONA trial in the first quarter of 2025 and initiation of the LUGANO trial and the LUCIA trial; the belief that the interim results from the VERONA trial support DURAVYU\u2019s potential to advance to non-inferiority pivotal trials; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as \u201cwill,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cintends,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cmay,\u201d other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint\u2019s actual results to be materially different than those expressed in or implied by EyePoint\u2019s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company\u2019s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company\u2019s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company\u2019s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company\u2019s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney\u2019s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company\u2019s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Precision AQ (formerly Stern IR) Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) September 30, December\u00a031, 2024 2023 Assets Current assets: Cash and cash equivalents $ 79,830 $ 281,263 Marketable securities 173,963 49,787 Accounts and other receivables, net 378 805 Prepaid expenses and other current assets 11,571 9,039 Inventory 2,807 3,906 Total current assets 268,549 344,800 Operating lease right-of-use assets 21,405 4,983 Other assets 10,963 5,401 Total assets $ 300,917 $ 355,184 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 21,509 $ 24,025 Deferred revenue 25,996 38,592 Other current liabilities 1,289 646 Total current liabilities 48,794 63,263 Deferred revenue - noncurrent 11,234 20,692 Operating lease liabilities - noncurrent 21,922 4,906 Other noncurrent liabilities 233 - Total liabilities 82,183 88,861 Stockholders' equity: Capital 1,049,180 1,007,605 Accumulated deficit (831,617 ) (742,146 ) Accumulated other comprehensive income 1,171 864 Total stockholders' equity 218,734 266,323 Total liabilities and stockholders' equity $ 300,917 $ 355,184 $ \u2014 $ \u2014 EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Unaudited (In thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenues: Product sales, net $ 664 $ 816 $ 2,390 $ 13,483 License and collaboration agreements 9,561 14,137 27,906 17,768 Royalty income 299 249 1,389 739 Total revenues 10,524 15,202 31,685 31,990 Operating expenses: Cost of sales 736 1,202 2,896 3,634 Research and development 29,542 17,363 89,554 46,711 Sales and marketing 24 479 80 11,504 General and administrative 12,970 10,556 39,770 28,854 Total operating expenses 43,272 29,600 132,300 90,703 Loss from operations (32,748 ) (14,398 ) (100,615 ) (58,713 ) Other income (expense): Interest and other income, net 3,387 1,786 11,144 4,611 Interest expense - - - (1,247 ) Loss on extinguishment of debt - - - (1,347 ) Total other income, net 3,387 1,786 11,144 2,017 Net loss $ (29,361 ) $ (12,612 ) $ (89,471 ) $ (56,696 ) Net loss per common share - basic and diluted $ (0.54 ) $ (0.33 ) $ (1.67 ) $ (1.50 ) Weighted average common shares outstanding - basic and diluted 54,449 38,341 53,526 37,804 View comments Terms and Privacy Policy Privacy Dashboard Recommended stories", "symbol": "EYPT", "date": "2024-11-07T12:00:00+00:00", "sentiment": {"score": 0.9268367225304246, "confidence": 0.9372339248657227, "probabilities": {"positive": 0.9372339248657227, "negative": 0.010397202335298061, "neutral": 0.0523688904941082}}, "embedding": [-0.06932186335325241, -0.1250305473804474, 0.09167328476905823, -0.05518179386854172, -0.07529406249523163, -0.15014421939849854, -0.06123250350356102, 0.22603534162044525, 0.074233278632164, 0.05596394091844559, -0.04420036822557449, 0.04880255460739136, 0.0034900400787591934, 0.020839139819145203, -0.011388170532882214, 0.03454938903450966, 0.04565894603729248, -0.03697801008820534, -0.06472606956958771, 0.10424080491065979, 0.09936244785785675, -0.036708079278469086, 0.025057567283511162, 0.04946257546544075, -0.08850916475057602, 0.07275416702032089, -0.03226719796657562, -0.037908896803855896, -0.10353464633226395, -0.15921086072921753, 0.026927584782242775, 0.09702672064304352, -0.057885557413101196, -0.07335976511240005, -0.023766834288835526, -0.030685927718877792, -0.13652168214321136, -0.03462981432676315, -0.15757368505001068, -0.02979200705885887, -0.043706782162189484, -0.01579280197620392, -0.17670699954032898, 0.10742777585983276, 0.11658207327127457, -0.20495176315307617, -0.056827422231435776, 0.06734178960323334, -0.0491662472486496, 0.16756731271743774, -0.13695429265499115, -0.08293204009532928, -0.0070604803040623665, 0.09591450542211533, -0.04268453270196915, 0.08089935034513474, -0.1526513546705246, -0.007435665000230074, 0.04890336096286774, -0.0369645431637764, 0.0006748372688889503, -0.03212754428386688, 0.010464923456311226, 0.03780505806207657, 0.02498292550444603, 0.02972833439707756, 0.07916820049285889, -0.0766979306936264, -0.014650272205471992, -0.05908190831542015, 0.03398042172193527, -0.017487533390522003, 0.04709877818822861, 0.018395835533738136, -0.025477074086666107, 0.09009472280740738, 0.14295217394828796, 0.03755820542573929, 0.08993807435035706, -0.14686059951782227, 0.1540442705154419, 0.07595743238925934, 0.07874923944473267, 0.010723291896283627, -0.0059190783649683, -0.019293654710054398, 0.05088731646537781, 0.07041839510202408, 0.030653174966573715, -0.0440036803483963, 0.1267317533493042, 0.034212879836559296, -0.07689405977725983, 0.0038787107914686203, -0.028818387538194656, -0.016594000160694122, -0.12602950632572174, -0.015771785750985146, -0.039790358394384384, 0.03897102549672127, 0.0458914153277874, 0.03610173240303993, -0.017836466431617737, -0.09572046250104904, -0.013500464148819447, -0.10580068826675415, 0.16845062375068665, -0.04001826420426369, 0.0024640255142003298, -0.01594739407300949, 0.006098919548094273, 0.03238433972001076, 0.029155563563108444, 0.04208149015903473, -0.036100730299949646, 0.17234984040260315, -0.13954897224903107, 0.014063834212720394, 0.29021862149238586, -0.05694429576396942, 0.1443156898021698, 0.004439792595803738, 0.023828450590372086, -0.1391163319349289, 0.06748044490814209, 0.042872846126556396, -0.03321124613285065, 1.1534059303495736e-32, 0.015337017364799976, -0.07223374396562576, -0.038255609571933746, 0.004975828342139721, -0.055100344121456146, -0.05733577907085419, 0.044224899262189865, 0.07620444893836975, -0.2355816662311554, -0.11771446466445923, -0.20234015583992004, -0.05386143550276756, -0.07375874370336533, 0.22942602634429932, -0.1439981907606125, -0.17426510155200958, 0.07617859542369843, 0.19115330278873444, -0.020038709044456482, 0.04025988280773163, 0.004088968969881535, 0.034331388771533966, -0.06317517906427383, 0.024893805384635925, -0.02569335140287876, 0.1299409419298172, -0.0512053519487381, 0.12333336472511292, 0.08408196270465851, 0.0747549906373024, -0.1298900693655014, 0.08942839503288269, 0.10459527373313904, -0.10544785857200623, -0.03403477743268013, -0.046152643859386444, -0.0046900431625545025, -0.12356429547071457, 0.06772834807634354, 0.040239982306957245, 0.015084714628756046, 0.1427297592163086, -0.08595933020114899, -0.13462840020656586, -0.005725707858800888, -0.05434919148683548, -0.09720329940319061, 0.04614678770303726, -0.027490314096212387, -0.08560802042484283, -0.040877632796764374, 0.015260811895132065, -0.06992855668067932, -0.09422129392623901, -0.055018819868564606, 0.0636330172419548, -0.16036346554756165, -0.11318264901638031, 0.10060737282037735, 0.058439575135707855, 0.03149023279547691, 0.10288695991039276, -0.05101393908262253, 0.0761246532201767, -0.14857544004917145, 0.040785957127809525, 0.040762629359960556, 0.011446012184023857, -0.12145885080099106, -0.020183315500617027, -0.05001983046531677, -0.042233049869537354, 0.12138094007968903, -0.01612802967429161, 0.17475223541259766, -0.05734792724251747, 0.13208350539207458, 0.11639156937599182, 0.1134500801563263, 0.03380226716399193, -0.0019440893083810806, -0.008132287301123142, -0.08704075217247009, 0.10574285686016083, 0.02382976934313774, -0.05381955951452255, 0.046052612364292145, -0.024087365716695786, -0.1735052615404129, -0.0555744543671608, 0.11078231781721115, 0.004457005299627781, -0.07721861451864243, 0.008806031197309494, 0.06464289873838425, -1.2040675328181064e-32, -0.014154679141938686, 0.0369567908346653, 0.027642643079161644, 0.045702461153268814, -0.025556201115250587, 0.08776605129241943, 0.031351275742053986, -0.02933751791715622, 0.1444569230079651, -0.15567336976528168, 0.021588506177067757, 0.0036125415936112404, -0.060751885175704956, -0.0946665108203888, -0.08606137335300446, 0.09599447250366211, -0.025432124733924866, -0.08115310966968536, -0.12591350078582764, 0.06562905758619308, 0.1624356210231781, 0.05899115279316902, -0.06266117841005325, -0.035743385553359985, 0.05737007409334183, 0.07895510643720627, 0.15708699822425842, -0.008275195956230164, -0.04115407541394234, -0.04314934089779854, -0.13182809948921204, 0.03028060495853424, -0.22853043675422668, 0.028379999101161957, -0.06627368927001953, 0.07150550186634064, 0.02585243433713913, -0.21738776564598083, -0.12660899758338928, -0.029091686010360718, 0.08647780865430832, -0.02399057149887085, 0.014143452048301697, 0.004065202083438635, 0.08607502281665802, 0.0535353422164917, 0.11500900983810425, -0.014220155775547028, 0.1176963746547699, 0.025804754346609116, -0.0840570256114006, 0.05003909766674042, 0.019148092716932297, 0.0121141467243433, -0.03856300935149193, -0.06750242412090302, 0.039519138634204865, -0.06258723884820938, -0.0271413866430521, 0.04507714509963989, 0.023387273773550987, 0.007979266345500946, -0.044410109519958496, -0.013674160465598106, 0.05437633395195007, 0.11774345487356186, 0.0931248888373375, -0.014784269966185093, 0.07824629545211792, -0.09023034572601318, -0.018173599615693092, -0.11912566423416138, -0.1332930326461792, -0.16759470105171204, 0.02190230041742325, 0.15213534235954285, -0.05336690694093704, -0.15798676013946533, -0.1599496304988861, 0.019150158390402794, 0.04537064582109451, -0.07303775101900101, -0.006812789011746645, 0.11480535566806793, 0.013822710141539574, 0.13553458452224731, 0.06500213593244553, -0.1049443781375885, -0.0108795166015625, 0.0969129130244255, -0.15929438173770905, -0.11065290868282318, -0.14304226636886597, 0.16656696796417236, 0.050785455852746964, -1.0099394387452776e-07, 0.005045032128691673, 0.02350962907075882, 0.05288948863744736, -0.01040535420179367, 0.07101795822381973, -0.1498875916004181, -0.07215917855501175, 0.1122172474861145, -0.037226319313049316, 0.11918336153030396, 0.036910444498062134, 0.12142306566238403, -0.06202516704797745, -0.024432482197880745, 0.06489984691143036, 0.1065666526556015, 0.04124775156378746, 0.0651630312204361, -0.08976796269416809, -0.0551513209939003, -0.11332401633262634, -0.009310172870755196, 0.135308176279068, -0.12475845217704773, 0.05132999271154404, -0.02628183923661709, -0.033560942858457565, 0.11315485835075378, 0.004695768468081951, -0.08813220262527466, 0.13493874669075012, 0.02190577983856201, 0.05931568890810013, -0.04201464354991913, -0.002999724820256233, -0.161210298538208, 0.05894473195075989, 0.18228992819786072, 0.11813076585531235, 0.1269279271364212, -0.10566198825836182, 0.06583679467439651, 0.07059763371944427, 0.08025574684143066, -0.004617653787136078, -0.05757114291191101, -0.0528707318007946, 0.009816084057092667, -0.04574055224657059, -0.1612858772277832, -0.07139669358730316, -0.04981093108654022, -0.027315648272633553, -0.02590453065931797, -0.02880372479557991, 0.11843852698802948, -0.014835568144917488, 0.026900514960289, -0.0677749440073967, -0.050420746207237244, 0.0646062046289444, -0.08724012970924377, -0.020744267851114273, 0.008233269676566124], "changes": {"1wk": -7.161345235364185, "1mo": -24.849008425576706}}, {"text": "EyePoint Pharmaceuticals: Q3 Earnings Snapshot Associated Press Finance Thu, Nov 7, 2024, 3:37 PM 1 min read In This Article: EYPT -6.27% WATERTOWN, Mass. (AP) \u2014 WATERTOWN, Mass. (AP) \u2014 EyePoint Pharmaceuticals (EYPT) on Thursday reported a loss of $29.4 million in its third quarter. On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 54 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share. The drug delivery technology company posted revenue of $10.5 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $12.4 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EYPT at https://www.zacks.com/ap/EYPT View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EYPT", "date": "2024-11-07T12:37:22+00:00", "sentiment": {"score": -0.9538612030446529, "confidence": 0.9625433683395386, "probabilities": {"positive": 0.008682165294885635, "negative": 0.9625433683395386, "neutral": 0.028774462640285492}}, "embedding": [0.000614236225374043, -0.017020318657159805, -0.04533987492322922, 0.08017577230930328, -0.024253912270069122, -0.03762461617588997, 0.003673830069601536, 0.21820662915706635, 0.12634427845478058, 0.016751857474446297, -0.007096273824572563, 0.10690384358167648, 0.01921723410487175, 0.03528820350766182, -0.05516627058386803, -0.031860001385211945, -0.03407913073897362, -0.07409677654504776, -0.03165170177817345, -0.03085283748805523, -0.030999602749943733, -0.0905940905213356, 0.11341679841279984, 0.04062730446457863, 0.09907743334770203, 0.15840604901313782, -0.09065070003271103, 0.03176651895046234, -0.09075436741113663, -0.08264368027448654, -0.050192251801490784, -0.013729032129049301, 0.14794209599494934, -0.14692135155200958, 0.05025355890393257, 0.020861739292740822, -0.08369211107492447, 0.006409116555005312, 0.04493493214249611, 0.007309880573302507, -0.04150281846523285, -0.0015392203349620104, -0.1322522759437561, -0.0034770818892866373, 0.09076976031064987, -0.19609035551548004, -0.05683675780892372, 0.07986516505479813, 0.002912368392571807, -0.01831279695034027, -0.15181368589401245, -0.13027898967266083, 0.06404820829629898, 0.015819799154996872, -0.10796795040369034, -0.02523060329258442, -0.14645420014858246, 0.005124327726662159, -0.00556408753618598, 0.06923822313547134, 0.10114704817533493, 0.05480356514453888, -0.006027051247656345, 0.0665634423494339, 0.0964687168598175, 0.14552542567253113, -0.03341662138700485, -0.024019988253712654, -0.05605968087911606, -0.03132392838597298, 0.004265062045305967, -0.06602896004915237, -0.07974181324243546, 0.0038682403974235058, -0.11201220750808716, 0.13080307841300964, 0.1541089564561844, 0.09457778185606003, -0.0272824726998806, 0.02281995676457882, 0.20964057743549347, -0.13823360204696655, -0.0987110361456871, 0.09513779729604721, -0.02966563031077385, -0.03212704882025719, 0.05576123297214508, 0.09939156472682953, 0.10089224576950073, -0.010983590967953205, 0.009951665997505188, -0.008685708045959473, -0.03564124554395676, -0.09531500935554504, 0.004277326166629791, 0.0017018862999975681, -0.16535022854804993, -0.14213334023952484, -0.06206650286912918, 0.002494542393833399, 0.10091106593608856, 0.08158514648675919, -0.02013605274260044, -0.11135095357894897, 0.06330102682113647, -0.05638423562049866, 0.1645798236131668, 0.11304422467947006, 0.024197064340114594, 0.09318848699331284, -0.08026037365198135, 0.035554949194192886, -0.10652441531419754, -0.04866638779640198, -0.03381017595529556, 0.11123685538768768, -0.07630196213722229, 0.03909359127283096, 0.16952089965343475, 0.08797619491815567, 0.0882965549826622, 0.18507613241672516, 0.05817204713821411, -0.09843602031469345, 0.06721565872430801, 0.025735070928931236, -0.12809450924396515, 4.54132038631036e-33, -0.010874209925532341, 0.16237831115722656, 0.02993236668407917, -0.1255849301815033, 0.0063834358006715775, -0.0003511723771225661, 0.08137580007314682, -0.1111389547586441, -0.0990280732512474, -0.0988021045923233, -0.11822530627250671, -0.014040124602615833, 0.025507258251309395, 0.024472065269947052, -0.07489556819200516, -0.004593423567712307, -0.007764485199004412, 0.052015580236911774, 0.004447960294783115, -0.06970745325088501, -0.03702373057603836, -0.12603844702243805, -0.09670340269804001, 0.016168605536222458, -0.032415758818387985, 0.10863298922777176, -0.07886660099029541, 0.15068702399730682, 0.016764001920819283, 0.007747018244117498, -0.028591621667146683, 0.1380101442337036, 0.07515032589435577, -0.1267259418964386, 0.06802641600370407, 0.006753904279321432, 0.02855498343706131, -0.02845768630504608, 0.17745807766914368, 0.055595945566892624, -0.07891371101140976, 0.12722192704677582, -0.0029895042534917593, -0.06002296507358551, -0.02548874169588089, 0.06817930191755295, -0.03567356616258621, 0.03615067899227142, 0.05262882634997368, -0.1326276808977127, -0.015695394948124886, 0.028643975034356117, -0.148981511592865, 0.07066996395587921, 0.017712831497192383, 0.03922978416085243, -0.02909262478351593, -0.17084497213363647, 0.0700886994600296, 0.06811832636594772, 0.03453931584954262, 0.217778280377388, 0.016726797446608543, -0.007966311648488045, -0.26568207144737244, 0.1078103706240654, 0.03189615160226822, 0.09367293864488602, -0.19481047987937927, 0.29061657190322876, 0.03355509042739868, -0.1411857157945633, 0.12141599506139755, 0.0030049446504563093, 0.1264011561870575, -0.07087752968072891, -0.05938734486699104, 0.020675159990787506, 0.15763290226459503, 0.051341887563467026, 0.11771763861179352, -0.09227950870990753, 0.12222040444612503, 0.0026318267919123173, 0.027965866029262543, -0.06398508697748184, 0.07874047756195068, -0.06355848163366318, -0.05176305025815964, 0.03809118643403053, 0.07529378682374954, -0.07773725688457489, -0.1388159990310669, 0.05780309438705444, -0.06489238142967224, -7.36239736037243e-33, -0.1379975825548172, 0.11802070587873459, 0.059639427810907364, -0.03406732901930809, -0.17696087062358856, -0.025668049231171608, 0.08485882729291916, 0.028062546625733376, 0.224502831697464, 0.16564083099365234, 0.014802834019064903, 0.07997579872608185, -0.1280059814453125, -0.0034206202253699303, -0.10874771326780319, 0.04290612041950226, 0.12145420908927917, -0.2621401846408844, -0.0005358977359719574, -0.10289090871810913, 0.1295737475156784, -0.030270004644989967, -0.11072270572185516, 0.15657396614551544, 0.04257495328783989, 0.11072342097759247, 0.11386885493993759, -0.04240117967128754, -0.035763658583164215, -0.09875503182411194, -0.06389769911766052, -0.06677982211112976, -0.090369313955307, 0.1264120191335678, -0.029103631153702736, 0.1738540083169937, 0.017409244552254677, -0.11853848397731781, -0.07484608143568039, -0.13938099145889282, 0.08372808247804642, -0.10122992098331451, -0.011920838616788387, 0.007264040410518646, 0.009349072352051735, 0.13281913101673126, 0.039712317287921906, 0.04957343637943268, 0.11980309337377548, 0.027457060292363167, -0.05769583210349083, 0.05261913314461708, -0.10390395671129227, 0.17421284317970276, -0.1684684455394745, 0.06447691470384598, 0.10865271091461182, 0.014317180961370468, -0.12150510400533676, 0.0018801367841660976, 0.04349835589528084, 0.002407470718026161, -0.10283289104700089, 0.09688282757997513, -0.05106355622410774, -0.045510292053222656, 0.11389072239398956, -0.012340125627815723, 0.13020098209381104, -0.18293222784996033, 0.06985201686620712, -0.06681432574987411, 0.13151347637176514, -0.15386775135993958, 0.009621036238968372, 0.307088166475296, -0.19348974525928497, -0.0513298362493515, -0.17230069637298584, 0.019419247284531593, 0.30991682410240173, 0.001909597311168909, 0.08296839147806168, 0.010957367718219757, -0.03348119184374809, 0.0290689654648304, 0.04915931075811386, -0.010777086950838566, -0.16070644557476044, 0.10134200006723404, -0.15163090825080872, -0.10082811862230301, -0.14391447603702545, 0.07356201857328415, 0.15520170331001282, -9.986891313928936e-08, -0.01695692166686058, -0.08644706010818481, 0.09728588908910751, 0.05048590898513794, -0.016887973994016647, -0.16001109778881073, 0.09857918322086334, 0.18407052755355835, -0.018251335248351097, 0.1464698165655136, -0.13359081745147705, -0.05989106744527817, -0.2730765640735626, 0.1939460039138794, -0.13244853913784027, -0.08856140822172165, 0.005028857383877039, 0.018184049054980278, 0.023432767018675804, -0.1623864471912384, -0.054757751524448395, 0.07678526639938354, 0.02509673871099949, -0.1639365404844284, 0.07188450545072556, -0.033000051975250244, -0.12324507534503937, 0.04358077049255371, -0.056516531854867935, -0.006560155656188726, 0.15666526556015015, -0.07393471896648407, 0.08178742229938507, 0.06462391465902328, -0.11170006543397903, -0.14493076503276825, 0.021518124267458916, 0.010670346207916737, 0.0042449068278074265, 0.06629260629415512, -0.15576030313968658, 0.009971486404538155, -0.04960609972476959, 0.04696134477853775, -0.030599193647503853, -0.03763506934046745, -0.18948408961296082, 0.008842779323458672, 0.07920630276203156, -0.21329131722450256, 0.17816196382045746, -0.12611506879329681, -0.032553091645240784, -0.03954773396253586, 0.05984668806195259, -0.08260108530521393, -0.07933279126882553, -0.060738176107406616, -0.10694412887096405, -0.13343371450901031, -0.006774147041141987, -0.29405710101127625, -0.004741739947348833, 0.11491327732801437], "changes": {"1wk": -7.161345235364185, "1mo": -24.849008425576706}}]